Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 736. Отображено 188.
12-08-1976 дата публикации

VERFAHREN ZUR HERSTELLUNG VON 2-METHYL3-HYDROXYMETHYL-PENTEN(1)-ON(4)

Номер: DE0002456514A1
Принадлежит:

Подробнее
13-03-1986 дата публикации

VERFAHREN ZUR HERSTELLUNG VON 5-ACYLPYRIMIDINEN

Номер: DE0003431689A1
Принадлежит:

Подробнее
15-08-1986 дата публикации

ARACHIDONSAEURE MORE SIMILARLY AND IT ABSTENTIONS ENTZUENDUNGSHEMMENDE ONE AND ANTIALLERGI MEANS.

Номер: AT0000020885T
Принадлежит:

Подробнее
15-09-1993 дата публикации

TERPENDERIVATE, YOUR PRODUCTION AND USE.

Номер: AT0000093833T
Принадлежит:

Подробнее
02-10-1996 дата публикации

Titanium catalyst, organotitanium reaction reagent, processes for producing these, and method of reaction using these

Номер: AU0004890096A
Автор: SATO FUMIE, FUMIE SATO
Принадлежит:

Подробнее
21-02-1989 дата публикации

PROCESS FOR THE PREPARATION OF ACETYLENIC DERIVATIVES, DERIVATIVES THUS MADE, AND THEIR USE

Номер: CA1250306A
Принадлежит: RHONE POULENC SANTE, RHONE-POULENC SANTE

L'invention concerne un procédé de préparation de dérivés acétyléniques de formule générale (I): = CH - R6 (I) dans laquelle R1 représente un atome d'hydrogène ou un radical phényle ou un radical de formule générale (II): (II) dans laquelle R2 et R3, identiques ou différents, représentent un atome d'hydrogène ou un radical aliphatique saturé ou non saturé éventuellement substitué, ou forment ensemble un radical cycloaliphatique, R4 représente un atome d'hydrogène ou un radical aliphatique saturé ou non saturé, un radical hydroxy, alcoyloxy, R5 représente un atome d'hydrogène ou un radical aliphatique saturé, R6 représente un atome d'hydrogène ou un radical aliphatique saturé ou non saturé, par action d'un dérivé acétylénique de formule générale (III): R1 - C ? C - H (III) sur un dérivé allylique de formule générale (IV) ou (V): (IV) (V) en présence d'un sel cuivreux et d'une base organique anhydre. L'invention concerne également les dérivés de formule générale (I) ainsi ...

Подробнее
07-03-1989 дата публикации

DERIVES D'ACIDE PROSTANOIQUE (ALPHA)-DIENIQUES

Номер: CA1250835A
Принадлежит: SEARLE & CO, SEARLE (G.D.) & CO.

... .alpha. CHAIN DIENIC PROSTANOIC ACID DERIVATIVES .alpha. diene 16-hydroxy prostanoic acid derivatives displaying valuable pharmacological properties, e.g., gastric antisecretory are described herein.

Подробнее
21-02-1989 дата публикации

PROCESS FOR THE PREPARATION OF ACETYLENIC DERIVATIVES, DERIVATIVES THUS MADE, AND THEIR USE

Номер: CA0001250306A1
Принадлежит:

Подробнее
12-08-1986 дата публикации

ARACHIDONIC ACID ANALOGUES AS ANTI-INFLAMMATORY AND ANTI-ALLERGIC AGENTS

Номер: CA0001209578A1
Автор: NELSON PETER H
Принадлежит:

Подробнее
05-07-2007 дата публикации

5-(AZIRIDIN-1-YL)-4-HYDROXYLAMINO-2-NITROBENZAMIDE

Номер: CA0002826746A1
Принадлежит:

There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.

Подробнее
22-12-1990 дата публикации

TERPENIC DERIVATIVES, PREPARATION AND USE THEREOF

Номер: CA0002019496A1
Принадлежит:

BREVET D'INVENTION NOUVEAUX DERIVES TERPENIQUES, LEUR PREPARATION ET LEUR EMPLOI RHONE-POULENC SANTE Nouveaux dérivés terpéniques de formule générale (I), leur préparation et leur emploi. Dans la formule générale (I), R représente un atome d'hydrogène ou un radical alcanoyle et R' représente un atome d'hydrogène ou un radical hydrocarboné aliphatique contenant éventuellement une ou plusieurs doubles liaisons. (I) ...

Подробнее
29-09-1978 дата публикации

Номер: CH0000605525A5

Подробнее
13-01-1978 дата публикации

Номер: CH0000594583A5
Принадлежит: BAYER AG

Подробнее
13-01-1978 дата публикации

Номер: CH0000594584A5
Принадлежит: BAYER AG

Подробнее
25-04-2007 дата публикации

PROCESS FOR THE PREPARATION OF PHYTONE, INTERMEDIATE AND PROCESS FOR THE PREPARATION THEREOF

Номер: UA0000078754C2
Автор:
Принадлежит:

Подробнее
15-02-1980 дата публикации

PROCESS FOR THE PREPARATION OF UNSATURATED KETONES

Номер: FR0002340923B1
Автор:
Принадлежит:

Подробнее
21-10-1983 дата публикации

ALCOOL OPTIQUEMENT ACTIF ET SA PREPARATION

Номер: FR0002525213A
Принадлежит:

LA PRESENTE INVENTION CONCERNE UN ALCOOL OPTIQUEMENT ACTIF REPRESENTE PAR LA FORMULE I: (CF DESSIN DANS BOPI) QUI EST UN COMPOSE INTERESSANT EN TANT QUE PRODUIT INTERMEDIAIRE D'INSECTICIDES DE LA SERIE DES PYRETHROIDES, AINSI QU'UN PROCEDE POUR SA PREPARATION.

Подробнее
24-05-1985 дата публикации

PROCEDE DE PREPARATION DE DERIVES ACETYLENIQUES, NOUVEAUX DERIVES OBTENUS ET LEUR EMPLOI

Номер: FR0002555164A
Принадлежит:

PROCEDE DE PREPARATION DE DERIVES ACETYLENIQUES DE FORMULE GENERALE I DANS LAQUELLE R REPRESENTE UN ATOME D'HYDROGENE OU UN RADICAL PHENYLE OU UN RADICAL DE FORMULE GENERALE II DANS LAQUELLE R ET R, IDENTIQUES OU DIFFERENTS, REPRESENTENT UN ATOME D'HYDROGENE OU UN RADICAL ALIPHATIQUE SATURE OU NON SATURE EVENTUELLEMENT SUBSTITUE, OU FORMENT ENSEMBLE UN RADICAL CYCLOALIPHATIQUE, R REPRESENTE UN ATOME D'HYDROGENE OU UN RADICAL ALIPHATIQUE SATURE OU NON SATURE, UN RADICAL HYDROXY, ALCOYLOXY, METHANESULFONYLOXY, BENZENESULFONYLOXY OU P.TOLUENESULFONYLOXY, R REPRESENTE UN ATOME D'HYDROGENE OU UN RADICAL ALIPHATIQUE SATURE, R REPRESENTE UN ATOME D'HYDROGENE OU UN RADICAL ALIPHATIQUE SATURE OU NON SATURE, PAR ACTION D'UN DERIVE ACETYLENIQUE DE FORMULE GENERALE III SUR UN DERIVE ALLYLIQUE DE FORMULE GENERALE IV OU V, EN PRESENCE D'UN SEL CUIVREUX ET D'UNE BASE ORGANIQUE ANHYDRE. LES PRODUITS DE FORMULE GENERALE I SONT UTILES EN SYNTHESE ORGANIQUE, EN PARTICULIER DANS LA PREPARATION DES VITAMINES ...

Подробнее
28-12-1990 дата публикации

NEW TERPENIC DERIVATIVES, THEIR PREPARATION AND THEIR EMPLOYMENT

Номер: FR0002648813A1
Принадлежит: Rhone Poulenc Sante SA

Nouveaux dérivés terpéniques de formule générale I, leur préparation et leur emploi. Dans la formule générale I, R représente un atome d'hydrogène ou un radical alcanoyle et R' représente un atome d'hydrogène ou un radical hydrocarboné aliphatique contenant éventuellement une ou plusieurs doubles liaisons. (CF DESSIN DANS BOPI)

Подробнее
08-01-1993 дата публикации

Compound having activity as a collagenase inhibitor and medicament containing it

Номер: FR0002678614A1
Принадлежит:

L'invention a pour objet un composé de formule I (CF DESSIN DANS BOPI) dans laquelle A est une chaîne linéaire hydrocarbonée en C1 1 -C1 9 saturée ou comprenant une ou plusieurs insaturations éthylénique ou acétylénique et R est choisi parmi les groupes 2-furanyle ou X-O-CH2 -CHOH-CH2 -C(=O) où X est l'atome d'hydrogène ou un groupe acétyle. Utilisation comme médicament, notamment comme inhibiteur de la collagénase.

Подробнее
09-09-1977 дата публикации

PROCESS FOR THE PREPARATION OF UNSATURATED KETONES

Номер: FR0002340923A1
Автор: [UNK]
Принадлежит: Kuraray Co Ltd

Подробнее
28-03-1986 дата публикации

MANUFACTURE OF 5-ACYLPYRIMIDINES

Номер: JP0061060662A
Принадлежит:

Подробнее
27-08-2007 дата публикации

СПОСОБ ПОЛУЧЕНИЯ ФИТОНА

Номер: RU2305091C2
Принадлежит: АДИССЕО ФРАНС С.А.С (FR)

Изобретение относится к способу получения соединения формулы (I), включающему взаимодействие соединения формулы (II) с соединением формулы (III) в присутствии катализатора, выбранного из катионных комплексов двухвалентного рутения, и полярного органического растворителя. Изобретение также относится к новому соединению формулы (I), которое используют при получении фитона и витамина Е, а также к способу получения фитона. 3 н. и 17 з.п. ф-лы, 2 табл.

Подробнее
27-01-2006 дата публикации

СПОСОБ ПОЛУЧЕНИЯ ФИТОНА

Номер: RU2004124826A
Принадлежит:

... 1. Способ получения соединения формулы (I) (1) который включает в себя взаимодействие соединения формулы (II) с соединением формулы (III) в присутствии катализатора и полярного растворителя. 2. Способ по п.1, в котором полярный растворитель выбирают из диметилформамида, диметилацетамида, диметилсульфоксида или N-метилпирролидона. 3. Способ по п.1, в котором катализатор выбирают из катионных комплексов двухвалентного рутения, таких как гексафторофосфат трис-ацетонитрил-циклопентадиенилрутения или гексафторофосфат трис-ацетонитрилпентаметил-циклопентадиенилрутения. 4. Способ по п.2, в котором катализатор выбирают из катионных комплексов двухвалентного рутения, таких как гексафторофосфат трис-ацетонитрил-циклопентадиенилрутения или гексафторофосфат трис-ацетонитрилпентаметил-циклопентадиенилрутения. 5. Способ по п.1, который проводят в присутствии второго растворителя, причем указанный второй растворитель не смешивается с первым растворителем. 6. Способ по п.2, который проводят в присутствии ...

Подробнее
17-10-1991 дата публикации

VERFAHREN ZUR HERSTELLUNG VON 5-ACYLPYRIMIDINEN.

Номер: DE0003584057D1
Принадлежит: BAYER AG, BAYER AG, 5090 LEVERKUSEN, DE

... (A)5-Acylpyrimidines of formula (Ia) are new R11 = alkyl (other than 1-4C n-alkyl), alkenyl, alkynyl, opt. substd. cycloalkyl, opt. substd. cycloalkylalkyl, opt. sybstd. phenyl (other than 2-hydroxyphenyl, opt. substd. heteroaryl or Q; Q = 1-halo-2-methyl-2-propyl, 1,3-dihalo-2-methyl-2-propyl, CMe2R5 or CMe2(CH2)nR6; R5 = alkyl,alkynyl or opt. derivatised CHO; R6 = CN, opt. substd. phenyl, XR7 or CONR8R9; R7 = alkyl, haloalkyl or opt. substd. phenyl or phenylalkyl; X = O or S; R8 = H, alkyl or opt. substd. phenyl; R9 = H or alkyl; n = 0-2. (B) Prodn. of 5-acylpyrimidines of formula (I) is effected by (a) reacting a methyl ketone of formula (II) with a formylating agent in the presence of a base and opt. acidifying the prod., reacting the resulting enol ketone (III) with formamidine or a formamidinium salt, reacting the resulting formamidine deriv. (IV) with an aminoformylating agent (V), and thermally cyclising the prod. (Va).; or (b) reacting (II) with a formylating agent in the presence ...

Подробнее
08-10-1969 дата публикации

A Process for the Production of Unsaturated Alcohols

Номер: GB0001166557A
Автор:
Принадлежит:

... 1,166,557. Substituted allyl alcohols. ROUREBERTRAND FILS & JUSTIN DUPONT S.A. DES ETABS. 7 March, 1967 [30 March, 1966], No. 10619/67. Heading C2C. Compounds of formula CH 2 : CR3CR1R2OH, where R1 and R3 are H or hydrocarbyl and R2 is hydrocarbyl substituted by OH (possibly etherified or esterified), or oxo or R2R2 with the adjacent C atoms form a polycyclic ring system, are prepared by reacting an epoxide with a compound AlR4R5R6, where R4, R5 and R6 are alkyl or alkenyl, or R5 is H, and hydrolysing the product. Where R2 in the starting material contains an oxo group, this may be in the form of a cyclic ketal with ethylene glycol, and subsequently the protecting group is removed by hydrolysis. Epoxides are prepared using monoperphthalic acid.

Подробнее
10-02-1969 дата публикации

Procedure for the production of insatiated alcohols

Номер: AT0000268222B
Автор:
Принадлежит:

Подробнее
15-02-1977 дата публикации

VERFAHREN ZUR HERSTELLUNG VON OXOVERBINDUNGEN DURCH KATALYTISCHE ISOMERISIERUNG

Номер: ATA321375A
Автор:
Принадлежит:

Подробнее
15-02-1977 дата публикации

PROCEDURE FOR THE PRODUCTION OF OXOVERBINDUNGEN BY CATALYTIC ISOMERIZATION

Номер: AT0000321375A
Автор:
Принадлежит:

Подробнее
17-03-1988 дата публикации

ISOPRENE DERIVATIVES

Номер: AU0007796687A
Принадлежит:

Подробнее
27-10-1978 дата публикации

PROCESS FOR THE PREPARATION OF BETA-HYDROXY-CARBONYL COMPOUNDS

Номер: FR0002260557B1
Автор:
Принадлежит:

Подробнее
28-02-1986 дата публикации

DERIVED 6-ALKYLES Of ACID 1,2-DIHYDRO-2-OXONICOTINIQUE AND PHARMACEUTICAL COMPOSITION the CONTAINER

Номер: FR0002446819B1
Автор: [UNK]
Принадлежит: Upjohn Co

Подробнее
21-11-1980 дата публикации

ESTERS DE DERIVES DE L'ALLETHROLONE ET D'ACIDES CYCLOPROPANE CARBOXYLIQUES, LEURS PROCEDES DE PREPARATION ET LES COMPOSITIONS LES RENFERMANT

Номер: FR0002455025A
Автор:
Принадлежит:

L'INVENTION A POUR OBJET LES COMPOSES DE FORMULE GENERALEI: (CF DESSIN DANS BOPI) DANS LAQUELLE R ET R REPRESENTENT NOTAMMENT DE L'HYDROGENE, UN ATOME D'HALOGENE, UN RADICAL ALCOYLE, R ET R REPRESENTANT NOTAMMENT UN ATOME D'HYDROGENE OU UN RADICAL ALCOYLE, Y REPRESENTE: -SOIT UN GROUPEMENT DERIVE D'UN ACIDE CYCLOPROPANE CARBOXYLIQUE; -SOIT UN GROUPEMENT DERIVE D'UN ACIDE 2-PHENYL 2-ALCOYLE ACETIQUE SUBSTITUE. L'INVENTION A EGALEMENT POUR OBJET DES PROCEDES DE PREPARATION DES COMPOSESI. LES COMPOSES(I) SONT DOUES DE PROPRIETES INSECTICIDES, ACARICIDES, NEMATOCIDES, ANTIFONGIQUES. ILS MANIFESTENT UNE ACTION REPULSIVE VIS-A-VIS DES ACARIENS PARASITES DES VEGETAUX.

Подробнее
21-10-1983 дата публикации

OPTICALLY ACTIVE ALCOHOL AND SA PREPARATION

Номер: FR0002525213A1
Принадлежит:

Подробнее
27-08-2009 дата публикации

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES

Номер: WO2009105123A1
Принадлежит:

The present invention provides compounds of Formula (I), compositions comprising an effective amount of a Compound of Formula (I), optionally with a tubulin-binding drug, methods of their use for treating or preventing cancer or a neurotrophic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, and methods for making Compounds of the invention.

Подробнее
27-05-2013 дата публикации

ПРИМЕНЕНИЕ 5-(АЗАРИДИН-1-ИЛ)-4-ГИДРОКСИЛАМИНО-2НИТРОБЕНЗАМИДА В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА ДЛЯ БОРЬБЫ С НЕЖЕЛАТЕЛЬНЫМ РОСТОМ ИЛИ ПРОЛИФЕРАЦИЕЙ КЛЕТОК

Номер: RU2011146556A

1. Фармацевтическая композиция, содержащая 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически примелемый носитель.2. Применение 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамида в производстве лекарственного средства для борьбы с нежелательным ростом или пролиферацией клеток у индивидуума.3. Применение по п.2, при котором нежелательный рост или пролиферация клеток у индивидуума являются доброкачественными и представляют собой бородавку или псориаз, или предраковую гиперплазию.4. Применение по п.4, при котором нежелательный рост или пролиферация клеток у индивидуума являются неопластическими.5. Применение по п.4, при котором нежелательный рост или пролиферация клеток у индивидуума являются опухолевыми.6. Фармацевтическая композиция по п.1, которая представляет собой раствор или суспензию, содержащие 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель.7. Раствор или суспензия, содержащие 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель, и являющиеся распыляемыми.8. Раствор или суспензия по п.7, применяемые для лечения рака мочевого пузыря, цервикального рака, рака яичника или рака головного мозга.9. Раствор или суспензия по п.7, применяемые для лечения рака рта, носовой полости, горла, глотки, гортани, трахеи или легких.10. Механический распылитель, имеющий резервуар, нагруженный раствором или суспензией, содержащими 5-(азаридин-1-ил)-4-гидроксиламино-2-нитробензамид и фармацевтически приемлемый адьювант, разбавитель или носитель.11. Аэрозольное устройство, содержащее раствор или � РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2011 146 556 A (51) МПК A61K 31/045 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2011146556/15, 16.11.2011 (71) Заявитель(и): МОРВУС ТЕКНОЛОДЖИ ЛИМИТЕД (GB) Приоритет(ы): (30) Конвенционный приоритет: 29.12.2005 GB 0526552.5 (72) Автор(ы): НОКС ...

Подробнее
07-05-2019 дата публикации

Номер: RU2017122232A3
Автор:
Принадлежит:

Подробнее
10-10-1977 дата публикации

PROCEDURE FOR THE PRODUCTION OF OXOVERBINDUNGEN BY CATALYTIC ISOMERIZATION

Номер: AT0000339270B
Автор:
Принадлежит:

Подробнее
15-02-2002 дата публикации

PRODUCTION OF BETA KETO ALCOHOLS

Номер: AT0000212967T
Принадлежит:

Подробнее
17-07-2003 дата публикации

PROCESS FOR THE PREPARATION OF PHYTONE

Номер: CA0002473367A1
Автор: ANCEL, JEAN ERICK
Принадлежит:

A process for the preparation of a novel intermediate compound useful in the preparation of phytone and vitamin E.

Подробнее
17-01-1992 дата публикации

TERPENE DERIVATIVES, THEIR PREPARATION AND USE

Номер: FR0002648813B1
Принадлежит: Rhone Poulenc Sante SA

Подробнее
04-05-1979 дата публикации

NEW TERTIARY ALCOHOLS AND PHARMACEUTICAL COMPOSITIONS AND PESTICIDES THE CONTAINER

Номер: FR0002405233A1
Автор:
Принадлежит:

Подробнее
05-11-1999 дата публикации

NEW COMPOSE EXTRACTED From PLANT OIL USABLE IN the DRUG COMPANY AND COSMETIC, IN PARTICULAR FOR the INHIBITION OF the CELL MULTIPLICATION

Номер: FR0002778181A1
Принадлежит: Laboratoires Pharmascience SA

The invention concerns a compound of formula (I) wherein: R' is H or a carboxylic acid acyl radical (a); R is a C13-C21 hydrocarbon chain capable of comprising 1 to 4 ethenoid or acetylene unsaturations.

Подробнее
10-06-2016 дата публикации

CATALYTIC OXIDATION OF BUT-3-ENE -1,2-DIOL

Номер: FR0003029518A1
Принадлежит: ADISSEO FRANCE S.A.S.

L'invention concerne un procédé de synthèse d'un composé de formule (I) suivante ou l'un de ses sels, où R représente un groupe COOH, CH2OH ou CHO, comprenant l'étape selon laquelle on soumet le but-3-ène-1,2-diol (BDO) à une oxydation en présence d'un catalyseur, ledit catalyseur comprenant une phase active à base d'au moins un métal noble choisi parmi le palladium, l'or, l'argent, le platine, le rhodium, l'osmium, le ruthénium et l'iridium, et un support contenant des sites basiques. L'invention concerne aussi l'application de cette réaction à la préparation de composés biodisponibles de la méthionine notamment utilisés en nutrition animale.

Подробнее
25-06-1976 дата публикации

METHOD OF PREPARATION OF 2-METHYl-3-HYDROXYMETHYL-PENTENE (1) - ONE (4)

Номер: FR0002292693A1
Автор:
Принадлежит:

Подробнее
13-01-1967 дата публикации

Process for the preparation of ketones

Номер: FR0001457155A
Автор:
Принадлежит:

Подробнее
21-11-1980 дата публикации

ESTERS AND DERIVATIVES [...] OF CYCLOPROPANE CARBOXYLIC ACIDS, METHODS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

Номер: FR0002455025A1
Автор: [UNK]
Принадлежит: Roussel Uclaf SA

L'INVENTION A POUR OBJET LES COMPOSES DE FORMULE GENERALEI: (CF DESSIN DANS BOPI) DANS LAQUELLE R ET R REPRESENTENT NOTAMMENT DE L'HYDROGENE, UN ATOME D'HALOGENE, UN RADICAL ALCOYLE, R ET R REPRESENTANT NOTAMMENT UN ATOME D'HYDROGENE OU UN RADICAL ALCOYLE, Y REPRESENTE: -SOIT UN GROUPEMENT DERIVE D'UN ACIDE CYCLOPROPANE CARBOXYLIQUE; -SOIT UN GROUPEMENT DERIVE D'UN ACIDE 2-PHENYL 2-ALCOYLE ACETIQUE SUBSTITUE. L'INVENTION A EGALEMENT POUR OBJET DES PROCEDES DE PREPARATION DES COMPOSESI. LES COMPOSES(I) SONT DOUES DE PROPRIETES INSECTICIDES, ACARICIDES, NEMATOCIDES, ANTIFONGIQUES. ILS MANIFESTENT UNE ACTION REPULSIVE VIS-A-VIS DES ACARIENS PARASITES DES VEGETAUX. THE SUBJECT OF THE INVENTION IS TO COMPOUNDS OF GENERAL FORMULA: (CF DRAWING IN BOPI) IN WHICH R AND R REPRESENT IN PARTICULAR HYDROGEN, A HALOGEN ATOM, A RADICAL ALCOHYL, R AND R REPRESENTING IN PARTICULAR A HYDROGEN ATOM OR AN ALCOHYL RADICAL, REPRESENTS IN IT: EITHER A GROUP DERIVED FROM A CYCLOPROPANE CARBOXYLIC ACID; - IS A GROUP DERIVED FROM A SUBSTITUTE 2-PHENYL 2-ALCOYL ACETIC ACID. THE INVENTION ALSO HAS A SUBJECT OF PROCESSES FOR THE PREPARATION OF COMPOSESI. COMPOUNDS (I) HAVE ANY INSECTICIDE, ACARICIDE, NEMATOCIDE, ANTIFUNGAL PROPERTIES. THEY MANIFEST A REPULSIVE ACTION AGAINST PLANT PARASITIC MITES.

Подробнее
28-12-1990 дата публикации

Nouveaux dérivés terpéniques, leur préparation et leur emploi

Номер: FR0002648813A
Автор: Claude Mercier
Принадлежит:

Nouveaux dérivés terpéniques de formule générale I, leur préparation et leur emploi. Dans la formule générale I, R représente un atome d'hydrogène ou un radical alcanoyle et R' représente un atome d'hydrogène ou un radical hydrocarboné aliphatique contenant éventuellement une ou plusieurs doubles liaisons.

Подробнее
15-03-1968 дата публикации

Process for the preparation of unsaturated alcohols

Номер: FR0001517179A
Автор:
Принадлежит:

Подробнее
01-04-1977 дата публикации

PREPARATION Of the 6,10,14-TRIMETHYLPENTADECA-2-ONE

Номер: FR0002322843A1
Автор:
Принадлежит:

Подробнее
05-03-1982 дата публикации

6-ALKYL-1, 2-DIHYDRO-2-OXO-PYRIDINES HAS SUBSTITUENT TETRAZOLYLE OR CARBOXALDEHYDE IN POSITION 3 AND PHARMACEUTICAL COMPOSITION the CONTAINER

Номер: FR0002489330A1
Принадлежит: Upjohn Co

L'INVENTION A TRAIT AU DOMAINE DE LA CHIMIE PHARMACEUTIQUE. ELLE CONCERNE DES 6-ALKYL-1, 2-DIHYDRO-2-OXO-PYRIDINES SUBSTITUEES EN POSITION 3 DE FORMULE: (CF DESSIN DANS BOPI) DANS LAQUELLE R EST UN RESTE ALKYLE EN C A C ET R EST UN GROUPE TETRAZOLYLE OU CARBOXALDEHYDE. LES COMPOSES DE L'INVENTION SONT DOUES D'ACTIVITE ANTIHYPERGLYCEMIQUE. THE INVENTION RELATES TO THE FIELD OF PHARMACEUTICAL CHEMISTRY. IT CONCERNS 6-ALKYL-1, 2-DIHYDRO-2-OXO-PYRIDINES SUBSTITUTED IN POSITION 3 OF FORMULA: (CF DRAWING IN BOPI) IN WHICH R IS AN ALKYL REMAIN IN C A C AND R IS A TETRAZOLYL OR CARBOXALDEH GROUP. THE COMPOUNDS OF THE INVENTION HAVE ANTIHYPERGLYCEMIC ACTIVITY.

Подробнее
12-03-2020 дата публикации

Fatty acid derivatives and uses thereof

Номер: KR1020200027545A
Принадлежит:

Подробнее
26-10-1982 дата публикации

Novel esters of 2-methyl-3-allyl-4-substituted-cyclopent-2-ene-1-yl

Номер: US0004356187A
Автор:
Принадлежит:

Novel esters of the formula I' wherein R1 and R2 are individually selected from the group consisting of carbamoyl and R1' and R2', R1' and R2' are individually selected from the group consisting of hydrogen, halogen, alkyl of 1 to 6 carbon atoms, aryl of 6 to 10 carbon atoms, aralkyl of 7 to 13 carbon atoms, alkoxycarbonyl of 2 to 5 carbon atoms and -CN, R3 and R3' are individually selected from the group consisting of hydrogen, halogen, alkenyl of 2 to 3 carbon atoms and alkyl of 1 to 3 carbon atoms, Y' is selected from the group consisting of +TR R4' and R5' are individually selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms, fluorine, bromine, chlorine and R4' and R5' together with the carbon atom to which they are attached form an optionally unsaturated hydrocarbon ring or heterocycle of 3 to 7 chain members and a heterocycle of the formula X is selected from the group consisting of sulfur and oxygen or R4' is cyano and R5' is ...

Подробнее
06-05-1941 дата публикации

Manufacture of beta-diketones

Номер: US2240934A
Автор:
Принадлежит:

Подробнее
20-03-2012 дата публикации

ПРИМЕНЕНИЕ АЛЬФА-ГИДРОКСИКАРБОНИЛЬНЫХ СОЕДИНЕНИЙ В КАЧЕСТВЕ ВОССТАНАВЛИВАЮЩИХ ВЕЩЕСТВ

Номер: RU2445078C2

FIELD: medicine, pharmaceutics. SUBSTANCE: declared invention refers to chemical-pharmaceutical industry and concerns the use of alpha-hydroxycarbonyl compounds as reducing substances able to form cyclic dimers. Also, there are presented related methods for reducing the reduced compounds, especially activated by compound reduction. The examples of the used alpha-hydroxycarbonyl compounds are dihydroacetone, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone. EFFECT: reduction takes place in mild conditions and provides selective production of one of isomers of the reduced compound. 54 cl, 9 ex, 7 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 445 078 (13) C2 (51) МПК A61K A61K A61K A61P 31/045 31/357 31/396 35/00 (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2008131054/15, 29.12.2006 (24) Дата начала отсчета срока действия патента: 29.12.2006 (73) Патентообладатель(и): МОРВУС ТЕКНОЛОДЖИ ЛИМИТЕД (GB) R U Приоритет(ы): (30) Конвенционный приоритет: 29.12.2005 GB 0526552.5 (72) Автор(ы): НОКС Ричард Джон (GB) (43) Дата публикации заявки: 10.02.2010 Бюл. № 4 C 2 2 4 4 5 0 7 8 C 2 R U (56) Список документов, цитированных в отчете о поиске: Knox RJ, Chen S., Quinone reductase-mediated nitro-reduction: clinical applications., Methods Enzymol. 2004; 382, p.p.194-221. Knox RJ, et al., Identification, synthesis and properties of 5(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem Pharmacol. 1993, V.46, №5, p.p.797-803. Kammerer (см. прод.) (85) Дата начала рассмотрения заявки PCT на национальной фазе: 29.07.2008 (86) Заявка PCT: GB 2006/004947 (29.12.2006) (87) Публикация заявки РСТ: WO 2007/074344 (05.07.2007) Адрес для переписки: 103735, Москва, ул. Ильинка, 5/2, ООО "Союзпатент", пат.пов. А.П.Агурееву (54) ПРИМЕНЕНИЕ АЛЬФА-ГИДРОКСИКАРБОНИЛЬНЫХ СОЕДИНЕНИЙ В КАЧЕСТВЕ ВОССТАНАВЛИВАЮЩИХ ВЕЩЕСТВ (57) Реферат: ...

Подробнее
22-11-2019 дата публикации

КАТАЛИТИЧЕСКОЕ ОКИСЛЕНИЕ БУТ-3-ЕН-1,2-ДИОЛА

Номер: RU2707078C2

FIELD: chemistry.SUBSTANCE: invention relates to a method for synthesis of at least one compound of formula (I) or one of its salts, in which R is a group of COOH, CHOH or CHO, where but-3-ene-1,2-diol (BDO) is subjected to oxidation in the presence of a catalyst containing an active phase based on at least one noble metal selected from palladium, gold, silver, platinum, rhodium, osmium, ruthenium and iridium, and a substrate containing alkaline sites and selected from hydrotalcites (HT), brucites, hydroxyapatite Ca(PO)(OH), tricalcium phosphate Ca(PO), calcium hydrophosphate CaHPO(0–2) HO, calcium diphosphate CaPO, octaculphosphate CaH(PO).5HO, tetrapotassium phosphate Ca(PO)O, amorphous calcium phosphates Ca(PO).nHO, oxides, hydroxides, carbonates, bicarbonates, phosphates, diphosphates and hydrophosphates of calcium, cesium, lithium, rubidium, potassium, magnesium, barium, cerium, lanthanum, aluminum, zinc, copper and their mixtures.Formula (I).EFFECT: invention also relates to use of said reaction for producing bio-accessible methionine compounds used, in particular, for feeding animals.11 cl, 2 dwg, 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 707 078 C2 (51) МПК C07C 45/37 (2006.01) C07C 319/18 (2006.01) C07C 323/22 (2006.01) C07C 323/52 (2006.01) C07C 49/24 (2006.01) C07C 49/258 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА C07C 51/235 (2006.01) ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ C07C 59/76 (2006.01) (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07C 45/37 (2019.08); C07C 319/18 (2019.08); C07C 323/22 (2019.08); C07C 323/52 (2019.08); C07C 49/24 (2019.08); C07C 49/258 (2019.08); C07C 51/235 (2019.08); C07C 59/76 (2019.08) (21)(22) Заявка: 2017122232, 07.12.2015 07.12.2015 Дата регистрации: 22.11.2019 Приоритет(ы): (30) Конвенционный приоритет: 05.12.2014 FR 1461964 (43) Дата публикации заявки: 09.01.2019 Бюл. № 1 (45) Опубликовано: 22.11.2019 Бюл. № 33 (86) Заявка PCT: C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 05.07.2017 (56) Список документов, ...

Подробнее
19-07-1978 дата публикации

UNSATURATED KETONES

Номер: GB0001518254A
Автор:
Принадлежит:

Подробнее
01-12-1976 дата публикации

PROCESS FOR THE MANUFACTURE OF OXO COMPOUNDS

Номер: GB0001457025A
Автор:
Принадлежит:

It has been found that secondary or tertiary acetylenecarbinols can be isomerised catalytically in a surprisingly simple manner with good yields and high conversion rates to give the corresponding alpha , beta -unsaturated aldehydes or ketones, when the isomerisation is carried out in the presence of a hydrocarbylsiloxyvanadium oxide catalyst of the formula in which KW denotes a hydrocarbon radical from the series consisting of lower alkyl, cycloalkyl, phenyl or phenyl-lower-alkyl, it being possible for the phenyl radical to be substituted by one or more electron-attracting groups, and R is KW or denotes the radical -Si(KW)3; m denotes the number 1, 2 or 3 and n denotes the number 0, 1 or 2, the total of m and n being 3, and in the presence of a silanol of the formula the catalyst of the formula III and/or the silanol of the formula IV having at least one phenyl radical which has one or more electron-attracting groups. Using this catalyst system, the isomerisation reactions ...

Подробнее
15-09-1989 дата публикации

PROCEDURE FOR THE PRODUCTION OF 2 (HYDROXYALKYL) ACRYLIC CONNECTIONS.

Номер: AT0000045720T
Принадлежит:

Подробнее
05-07-2007 дата публикации

Use of alpha-hydroxy carbonyl compounds as reducing agents

Номер: AU2006329678A1
Принадлежит:

Подробнее
27-02-1986 дата публикации

PROSTANOIC ACID DERIVATIVES

Номер: AU0000549996B2
Принадлежит:

Подробнее
05-07-2007 дата публикации

USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS

Номер: CA0002635388A1
Принадлежит:

There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction- activated prodrugs . Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde , glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.

Подробнее
06-09-1977 дата публикации

PROCESS FOR THE MANUFACTURE OF OXO COMPOUNDS

Номер: CA0001016937A1
Принадлежит:

Подробнее
17-04-1987 дата публикации

PROCEDE DE PREPARATION DE DERIVES HYDROXY-3 CETONIQUES

Номер: FR0002588567A
Принадлежит:

L'INVENTION SE RAPPORTE A UN PROCEDE DE PREPARATION DE COMPOSES COMPORTANT LA SEQUENCE ACYCLIQUE DE FORMULE : (CF DESSIN DANS BOPI) PROCEDE SUIVANT LEQUEL ON EFFECTUE, A UNE TEMPERATURE DE 30 A 37C, LA REDUCTION DE LA SEQUENCE ACYCLIQUE DICETONE-1,3 ENOLISABLE DE FORMULE : (CF DESSIN DANS BOPI) AU MOYEN DE SACCHAROMYCES CEREVISIAE.

Подробнее
08-05-1958 дата публикации

Method of preparation of the diisobutylcétone

Номер: FR0001155785A
Автор:
Принадлежит:

Подробнее
12-11-1982 дата публикации

PROCEDE D'ADDITION SELECTIVE D'UN COMPOSE A METHYLENE ACTIF SUR UN DIENE CONJUGUE SUBSTITUE ET NOUVEAUX COMPOSES RESULTANTS

Номер: FR0002505322A
Автор: DIDIER MOREL
Принадлежит:

PROCEDE D'ADDITION D'UN COMPOSE AYANT UN CARBONE TERTIAIRE ACTIVE SUR UN BUTADIENE-1,3 PORTANT UN SUBSTITUANT HYDROCARBONE SUR L'ATOME DE CARBONE 2, PROCEDE DU TYPE SELON LEQUEL ON FAIT REAGIR LE COMPOSE AYANT UN CARBONE TERTIAIRE ACTIVE ET LE BUTADIENE PORTANT UN SUBSTITUANT HYDROCARBONE DANS L'EAU OU DANS UN MELANGE HYDRO-ALCOOLIQUE EN PRESENCE D'UN CATALYSEUR CONSTITUE, D'UNE PART, PAR AU MOINS UNE PHOSPHINE SOLUBLE DANS L'EAU ET D'AUTRE PART, PAR AU MOINS UN COMPOSE D'UN METAL DE TRANSITION, LE CATALYSEUR ETANT EN SOLUTION DANS L'EAU OU LE MELANGE HYDRO-ALCOOLIQUE, PROCEDE CARACTERISE EN CE QUE, DANS LE BUT D'OBTENIR UNE ADDITION TOTALEMENT SELECTIVE DU COMPOSE A CARBONE TERTIAIRE ACTIVE SUR LE CARBONE 4 DU BUTADIENE-1,3 PORTANT UN SUBSTITUANT HYDROCARBONE SUR LE CARBONE 2, LE METAL DE TRANSITION MIS EN OEUVRE EST LE RHODIUM.

Подробнее
15-07-1997 дата публикации

Beta-keto-alcohols and the process for the manufacture thereof

Номер: US0005648550A1
Принадлежит: Roche Vitamins Inc.

A novel process for the manufacture of β-keto alcohols from aldehydes comprising reacting a conjugated polyene aldehyde under basic conditions with a cyclocarbonate or derivative thereof. Certain carotenoid products of this process are novel compounds and are also an object of the present invention. The products, which for the most part belong to the carotenoid field, find corresponding use, for example, as colorants or pigments for foodstuffs, egg yolk, integuments and/or subcutaneous fat of poultry and flesh and/or integuments of fish and crustaceans.

Подробнее
10-08-1982 дата публикации

Method for preparing 4-hydroxy-3-methyl-2-(2-propynyl)-2-cyclopentenolone

Номер: US0004343953A1
Принадлежит: Sumitomo Chemical Company, Limited

The present invention relates to a novel method for producing cyclopentenolone of the formula (I), см. иллюстрацию в PDF-документе which is a useful intermediate for producing agricultural chemicals, which comprises reacting an acetonedicarboxylic ester of the formula (VII), см. иллюстрацию в PDF-документе wherein R is a C1 -C6 alkyl group, with 2-propynyl chloride in the presence of magnesium alkoxide and in the presence of alkali iodide to obtain novel mono-(2-propynyl)-substituted acetonedicarboxylic ester of the formula (VI), см. иллюстрацию в PDF-документе wherein R is as defined above; hydrolyzing the mono-(2-propynyl)-substituted acetonedicarboxylic ester of the formula (VI) under alkaline conditions with an alkali and then reacting the hydrolyzed product with methylglyoxal of the formula, см. иллюстрацию в PDF-документе to obtain novel γ-diketone of the formula (V), см. иллюстрацию в PDF-документе and ring-closing the γ-diketone of the formula (V) under alkaline condition.

Подробнее
10-02-2010 дата публикации

ПРИМЕНЕНИЕ АЛЬФА-ГИДРОКСИКАРБОНИЛЬНЫХ СОЕДИНЕНИЙ В КАЧЕСТВЕ ВОССТАНАВЛИВАЮЩИХ ВЕЩЕСТВ

Номер: RU2008131054A

1. Применение соединения формулы I ! ! в которой R1 представляет собой Н, арил, Het или C1-12 алкил, последняя группа которого необязательно замещена одним или больше заместителями, выбранными из ОН, гало и С1-3 алкокси, ! R2 представляет собой Н или C1-6 алкил, последняя группа которого необязательно замещена одной или больше группами ОН, ! арил представляет собой С6-10 карбоциклическую ароматическую группу, которая может быть замещена одним или больше заместителями, выбранными из гало, C1-6 алкил и C1-6 алкокси, ! Het представляет собой 4-14 членную гетероциклическую группу, включающую один или больше гетероатом, выбранный из кислорода, азота и/или серы, гетероциклическую группу, которая может содержать одно, два или три кольца и может быть замещена одним или больше заместителями, выбранными из гало, C1-6 алкила и C1-6 алкокси, ! и характеризуется тем, что оно способно образовывать циклический димер, формулы Ia ! ! в которой R1 и R2 - как определено выше, ! в качестве активирующего агента для преобразования активируемого восстановлением пролекарства в соответствующее активное вещество. ! 2. Применение по п.1, при котором активируемое восстановлением пролекарство является одним или больше соединением, выбранным из: ! (a) Метронидазол (2-метил-5-нитро-1Н-имидазол-1-этанол); ! (b) Хлорамфеникол (2,2-дихлоро-N-[(αR,βR)-β-гидрокси-α-гидроксиметил-4-нитрофенэтил]ацетамид); ! (c) Нитрофуразон(2-[(5-нитро-2-фуранил)метилен]гидразинкарбоксамид); ! (d) E09 (3-[5-азиридинил-4,7-диоксо-3-гидроксиметил-1-метил-1Н-индол-2-ил]-проп-β-ене-α-ол); ! (e) SR-4233 (3-амино-1,2,4-бензотриазин-1,4-диоксид); ! (f) RSU-1069 (1-(1-азиридинил)-3-(2-нитро-1-имидазолил)-2-пропанол); ! (g) RB-6145 (1-[3-(2-бромоэтиламино)-2-гидроксипропил]-2-н РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2008 131 054 (13) A (51) МПК A61K 31/045 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (71) Заявитель(и): МОРВУС ТЕКНОЛОДЖИ ЛИМИТЕД (GB) (21), (22) ...

Подробнее
15-05-1988 дата публикации

Способ получения производных ацетилена

Номер: SU1396961A3

Изобретение касается производных ацетилена (АИ), в частности соединений общей формулы R,C ССН iC (СН j) . CHR, где R - 1-гидрокси-1-метилэ- ткл, 1,5-димeтил-1-гидpoкcи-4-гeк- ceнил, 1-гидрокси-1-метил-3-(1,6,6- триметил-1-циклогексенил)-2-пропенил, RJ - З-метилен-4-пентенил или Н, которые могут быть использованы как полупродукты для синтеза витамина А или Ео Синтез АП ведут реакцией производного ацетилена общей формулы R ,С СН и производного алкена общей формулы С1СН ,- С (СН з) CHR или СН 5 С(СНз) - CHC1R,, где R , и RJ - имеют указанные значения, в среде .: триэтиламина и присутствии катализатора иодида меди или хлорида меди, или. комплекса хлорида меди с 1,5-цик- лооктадиеном формулы CuCl (циклоок- тадиен-1,5)У, при нербходимости в присутствии сокатализатора - иодида калия в атмосфере аргона при 50-80 0. Выход АП 31,4 - 87%, селективность до 91%. Полученные АП позволяют синтезировать витамины А и Е по более простой технологии, используя мень- щее количество стадий. в S СУ) со со О5 СО ...

Подробнее
18-04-2002 дата публикации

New alpha-hydroxy-ketone derivatives, useful as intermediates for biologically active polyketides, terpenoids, epothilones and their derivatives

Номер: DE0010051136A1
Принадлежит:

... alpha -Hydroxy-ketone (acyloin) compounds (I), in non-racemic, optically active or racemic form at the alpha -hydroxy-position, and their hydroxy-protected derivatives are new. Also new are several classes of new intermediates for and conversion products of (I). alpha -Hydroxy-ketone (acyloin) compounds of formula (I), in non-racemic, optically active or racemic form at the alpha -hydroxy-position, and their hydroxy-protected derivatives are new: R1 = H, alkyl, aryl, aralkyl (e.g. arylmethyl or arylethyl), vinyl, alkynyl (preferably propynyl), allyl (preferably 3,3-dialkylallyl; sic), cycloalkyl (preferably 3-7 membered), CHnFn-3, oxacycloalkyl (preferably 3-7 membered) or a combination of these; R2 = alkyl, aryl, alkaryl (e.g. arylmethyl or arylethyl), vinyl, alkynyl (preferably propynyl), allyl (preferably alkylallyl, 3,3-dialkylallyl, E- or Z-3-haloallyl or 3,3-dihaloallyl; sic), cycloalkyl (preferably 3-7 membered), CHnFn-3, oxacycloalkyl (preferably 3-7 membered) or a combination of ...

Подробнее
17-03-1982 дата публикации

2-pyridinone derivatives

Номер: GB0002083024A
Принадлежит:

The present invention relates to certain 6-alkyl-1,2-dihydro-2-oxo-3-substituted pyridine derivatives, their preparation and antihyperglycemic use.

Подробнее
30-10-1980 дата публикации

ALLETHROLONE DERIVATIVES

Номер: AU0005779380A
Принадлежит:

Подробнее
24-04-1975 дата публикации

OXO COMPOUNDS

Номер: AU0006170673A
Принадлежит:

Подробнее
12-10-1976 дата публикации

2-(6-CARBOMETHOXY-CIS-2-HEXENYL)-4(R)-HYDROXY-2-CYCLOPENTEN-1-ONE AND METHOD FOR PREPARING SAME

Номер: CA998345A
Автор:
Принадлежит:

Подробнее
06-09-1977 дата публикации

PROCESS FOR THE MANUFACTURE OF OXO COMPOUNDS

Номер: CA1016937A
Автор:
Принадлежит:

Подробнее
04-10-1968 дата публикации

New halogenous céto-alcohols and their method of preparation

Номер: FR0001540910A
Автор:
Принадлежит:

Подробнее
04-05-1979 дата публикации

NOUVEAUX ALCOOLS TERTIAIRES ET COMPOSITIONS PHARMACEUTIQUES ET PESTICIDES LES CONTENANT

Номер: FR0002405233A
Автор:
Принадлежит:

L'invention a trait à de nouveaux alcools tertiaires de formule : ...

Подробнее
14-08-1980 дата публикации

Dérivés 6-alkylés d'acide 1,2-dihydro-2-oxonicotinique et composition pharmaceutique les contenant.

Номер: FR0002446819A
Принадлежит:

L'invention a trait au domaine de la chimie pharmaceutique. Elle concerne certains nouveaux dérivés 6-alkyliques d'acide 1,2-dihydro-2-oxonicotinique de formule ...

Подробнее
19-11-1976 дата публикации

PROCESS FOR THE MANUFACTURE OF OXO COMPOUNDS

Номер: FR0002205496B1
Автор:
Принадлежит:

Подробнее
25-06-1976 дата публикации

METHOD OF PREPARATION OF 2-ACETYL-3-METHYl-BUTADIENE (1,3)

Номер: FR0002292692A1
Автор:
Принадлежит:

Подробнее
28-08-1984 дата публикации

Process for the preparation of polyprenyl ketone derivatives

Номер: US0004468459A1

Longer carbon chain polyprenyl ketone derivatives are prepared by cultivag Nocardia strain FERM-P No. 1609 in the presence of shorter carbon chain polyprenyl ketones.

Подробнее
13-04-1993 дата публикации

Terpene derivatives, their preparation and their use

Номер: US0005202460A
Автор:
Принадлежит:

Terpene derivatives of formula I, their preparation and their use. In formula I, R represents a hydrogen atom or an alkanoyl radical and R' represents a hydrogen atom or an aliphatic hydrocarbon radical. ...

Подробнее
06-09-2012 дата публикации

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease

Номер: US20120225890A1
Принадлежит: ProteoTech Inc

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
25-04-2013 дата публикации

COMPOSITIONS AND METHODS FOR DETECTING AMYLOID-BETA-DEGRADING ENZYME ACTIVITY

Номер: US20130102498A1
Принадлежит: Academia Sinica

Novel substrates for detection of activity of amyloid beta degrading enzyme, such as Neprilysin (NEP) and insulin degrading enzyme (IDE), associated with Alzheimer's disease, are provided. A quenched fluorogenic peptide substrate containing the first seven residues of the Aβpeptide plus a C-terminal Cys residue to detect neprilysin activity with a fluorophore attached to the C-terminal Cys and a quencher linked to the N-terminus of the peptide is disclosed. An assay system sensitive to endopeptidase activity of NEP and IDE, but insensitive to other Aβ-degrading enzymes is disclosed. Active compounds are identified by a cell-based assay system for high-throughput screening. 1. A peptide substrate for detection of amyloid-β degrading enzyme activity , the substrate comprising:(a) a peptide of the sequence DAEFRHDC (SEQ ID NO: 1) comprising residues 1-7 of the amyloid-β peptide and a cysteine residue at the C-terminal end, or an analog or derivative thereof, wherein the peptide comprises a cleavage site for an amyloid-β degrading enzyme;(b) a quencher coupled to the N-terminal end of the peptide; and(c) a fluorophor coupled with the C-terminal end of the peptide.2. The substrate of claim 1 , wherein the amyloid-β degrading enzyme is selected from the group consisting of neprilysin (NEP) and insulin degrading enzyme (IDE).3. The substrate of claim 1 , wherein the fluorophore is selected from the group consisting of fluorescein claim 1 , fluorescein derivatives claim 1 , rhodamines claim 1 , tetramethylrhodamines claim 1 , coumarins claim 1 , resorufins claim 1 , pyrenes claim 1 , anthracenes claim 1 , phenylenes claim 1 , phthalocyanines claim 1 , cyanines claim 1 , xanthenes claim 1 , amidopyrylium dyes claim 1 , oxazines claim 1 , quadrain dyes claim 1 , carbopyronines claim 1 , NBD derivatives claim 1 , BODIPY fluorophores claim 1 , ALEXA fluorophores claim 1 , ALEXA-350 claim 1 , lanthanide chelates claim 1 , metalloporphyrins claim 1 , NIR fluorophores claim 1 , ...

Подробнее
19-09-2013 дата публикации

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE

Номер: US20130245128A1
Принадлежит:

The use of 3,4,3′,4′-tetrahydroxychalcone in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease. 1. A method of treating the formation , deposition , accumulation , or persistence of synuclein fibrils , comprising treating the fibrils with an effective amount of 3 ,4 ,3′ ,4′-tetrahydroxychalcone.2. The method of where the synuclein fibrils are α-synuclein fibrils.3. A method of treating the formation claim 1 , deposition claim 1 , accumulation claim 1 , or persistence of amyloid fibrils claim 1 , comprising treating the fibrils with an effective amount of 3 claim 1 ,4 claim 1 ,3′ claim 1 ,4′-tetrahydroxychalcone.4. The method of where the amyloid fibrils are Aβ amyloid fibrils.5. The method of where the amyloid fibrils are IAPP amyloid fibrils.6. A method of inhibiting and/or relieving an amyloid disease or a synucleinopathy in a mammal suffering therefrom claim 3 , comprising administration to the mammal of a therapeutically effective amount of 3 claim 3 ,4 claim 3 ,3′ claim 3 ,4′-tetrahydroxychalcone.7. The method of where the synucleinopathy is a disease associated with the formation claim 6 , deposition claim 6 , accumulation claim 6 , or persistence of synuclein fibrils.8. The method of where the synucleinopathy is a disease associated with the formation claim 6 , deposition claim 6 , accumulation claim 6 , or persistence of α-synuclein fibrils.9. The method of where the synucleinopathy is selected from the group of diseases consisting of Parkinson's disease claim 6 , familial Parkinson's disease claim 6 , Lewy body disease claim 6 , the Lewy body variant of Alzheimer's disease claim 6 , dementia with Lewy bodies claim 6 , multiple system atrophy claim 6 , and the Parkinsonism-dementia complex of Guam.10. The method of where the synucleinopathy is Parkinson's disease.11. The method of where the ...

Подробнее
07-11-2013 дата публикации

Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient

Номер: US20130296422A1
Принадлежит: ARIGEN PHARMACEUTICALS, INC.

Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) 2. The compound claim 1 , optical isomer thereof claim 1 , and pharmaceutically acceptable salt thereof of claim 1 , wherein the one or more substituents of Rare each any one of —COOH claim 1 , —COORa (wherein Ra represents a Calkyl group) claim 1 , —CHO claim 1 , —COOCHCH(OH)CHOH claim 1 , —COO—CH—Rb (wherein Rb represents a group formed by removing one hydrogen atom on a carbon atom of aromatic hydrocarbons claim 1 , such as benzene claim 1 , naphthalene claim 1 , and anthracene) claim 1 , —O—CO-Rc (wherein Rc represents a Calkyl group) claim 1 , —OH claim 1 , —O-Rd (Rd represents a Calkyl group) claim 1 , —O—CH—O—CH claim 1 , —HET (HET represents a group formed by removing one hydrogen atom on a carbon or nitrogen atom of heterocyclic compounds) claim 1 , and —O-HET (HET is defined as above).4. The pharmaceutical composition of claim 3 , wherein the one or more substituents of Ris any one of —COOH claim 3 , —COORa (wherein Ra represents a Calkyl group) claim 3 , —CHO claim 3 , —COOCHCH(OH)CHOH claim 3 , —COO—CH—Rb (wherein Rb represents a group formed by removing one hydrogen atom on a carbon atom of aromatic hydrocarbons claim 3 , such as benzene claim 3 , naphthalene claim 3 , and anthracene) claim 3 , —O—CO-Rc (wherein Rc represents a Calkyl group) claim 3 , —OH claim 3 , —O-Rd (wherein Rd represents a Calkyl group) claim 3 , —O—CH—O—CH claim 3 , —HET (wherein HET represents a group formed by removing one hydrogen atom on a carbon or nitrogen atom of heterocyclic compounds) claim 3 , and —O-HET (wherein HET is defined as above).5. The pharmaceutical composition of or claim 3 , further comprising glycerol.7Trypanosoma.. The agent of claim 6 , wherein the protozoans is8Cryptosporidium.. The agent of claim 6 , wherein the protozoans is9. The agent of any one of to claim 6 , further comprising glycerol.11. The kit of ...

Подробнее
07-11-2013 дата публикации

Novel Curcumin and Tetrahydrocurcumin Derivatives

Номер: US20130296527A1

The invention relates to novel curcumin and tetrahydrocurcumin derivatives, which have been modified at one phenolic group to incorporate more-reactive groups. The curcumin and tetrahydrocurcumin derivatives are in the form of monomers, dimmers, and polymers.

Подробнее
30-01-2014 дата публикации

Solid Forms of Curcumin

Номер: US20140031403A1
Принадлежит:

The present invention provides forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms. 1. A co-crystal form of curcumin , wherein the co-crystal form is curcumin-2-aminobenzimidazole.2. The co-crystal form of claim 1 , wherein curcumin-2-aminobenzimidazole exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees-2-theta at about 6.2 claim 1 , about 9.0 claim 1 , about 12.3 claim 1 , about 14.5 claim 1 , about 17.3 claim 1 , about 18.0 claim 1 , about 19.0 claim 1 , about 20.0 claim 1 , about 21.2 claim 1 , about 24.5 claim 1 , about 25.05 claim 1 , and about 27.1 claim 1 , and further exhibits an endothermic transition with an onset of about 118.1° C. as measured by differential scanning calorimetry.3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. A co-crystal form of curcumin claim 1 , wherein the co-crystal form is curcumin-L-lysine.9. The co-crystal form of claim 8 , wherein curcumin-L-lysine is an amorphous form of curcumin co-crystal; and exhibits a first exotherm at onset 36.7° C. with peak 43.6° C. claim 8 , a second exotherm at onset 93.7° C. with peak 97.8° C. claim 8 , and an endotherm at onset 135.5° C. with peak 136.0° C.10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. A polymorph form of curcumin claim 8 , wherein the polymorph form is Form III.16. The polymorph form of claim 15 , wherein Form III exhibits X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 9.56 claim 15 , about 14.51 claim 15 , about 17.90 claim 15 , and about 26.86 claim 15 , and exhibits an endothermic transition with an onset of about 162.6° C. as measured by differential scanning calorimetry. ...

Подробнее
06-02-2014 дата публикации

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease

Номер: US20140038980A1
Принадлежит: ProteoTech Inc

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
06-02-2014 дата публикации

Compositions and processes of preparing and using the same

Номер: US20140039182A1
Принадлежит: PURDUE RESEARCH FOUNDATION

The present invention relates to compositions, for example, the DBU/Hexafluoroacetone hydrate salt, and processes of preparing and using the same for the modification of chemical compounds via the release of trifluoroacetate. The DBU/Hexafluoroacetone hydrate salt can perform trifluoromethylation reactions on chemical compounds, such as carbonyl group-containing compounds.

Подробнее
27-03-2014 дата публикации

VIRAL INHIBITOR COMPOSITION FOR IN VIVO THERAPEUTIC USE

Номер: US20140088193A1
Автор: Coppens Christine
Принадлежит: CESA ALLIANCE S.A.

The present invention concerns a pharmaceutical composition comprising a compound of formula A being (2,3(dihydroxy), 5[3(1,2)butadiene], 1(3hydroxy,3methyl,4pentene)benzene) and/or a compound of formula B being (2,3(dihydroxy), 5[3(1,2)butadiene], 2[2methylbutane]benzenal) and/or a compound of formula C being (2,3(dihydroxy), 5[3(1,2)butadiene], 2hydroxy,3butene benzoate) or a combination thereof for use as a medicament or for in vivo use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses. 3. Composition according to or composition for use according to , wherein the compounds are selected from the group consisting in:the compound of formula A alone, orthe compound of formula B alone, orthe compound of formula C alone, orthe compound of formula A and the compound of formula B, orthe compound of formula A and the compound of formula C, orthe compound of formula B and the compound of formula C, orthe compound of formula A and the compound of formula B and the compound of formula C.4. Composition according to or composition for use according to , wherein each compound is administered at a dose higher than or equal to 0.1 mg per administering.5. Composition according to or composition for use according to , wherein each compound is administered at a dose comprised between 0.1 mg and 5000 mg per administering.6. Composition according to or , wherein the dose is administered at least one time per day.7macadamia. Composition according to or composition for use according to or composition according to , wherein a base oil such as olive oil , or oil is added.8. Composition according to or composition for use according to , wherein the composition is used as a prophylactic.9. Composition according to or composition for use according to , wherein the composition is used as a viral inhibitor within the body.10. Composition according to or composition for use according to , ...

Подробнее
06-01-2022 дата публикации

Half-Curcuminoids as Amyloid-Beta PET Imaging Agents

Номер: US20220001036A1
Принадлежит:

Provided herein are curcumin analogues that are able to interact with amyloid beta (Aβ) and to attenuate the copper-induced crosslinking of Aβ. Also provided herein are methods of using the compounds as imaging agents of amyloid beta and for the treatment of diseases associated with amyloid beta. Methods of preparing unlabeled and radiolabeled compounds useful for interacting with amyloid beta and pharmaceutical compositions are also provided. 2. The method of claim 1 , wherein the imaging technique is selected from the group consisting of fluorescence imaging claim 1 , positron emission tomography imaging claim 1 , magnetic resonance imaging claim 1 , single-photon emission computed tomography claim 1 , positron emission tomography with computed tomography imaging claim 1 , and positron emission tomography with magnetic resonance imaging.3. The method of claim 1 , wherein the imaging technique is selected from the group consisting of fluorescence imaging claim 1 , position emission tomography imaging claim 1 , and single-photon emission computed tomography.5. The method of claim 1 , wherein:{'sup': 4', '5, 'X is BRR;'}{'sup': 1', '1A, 'sub': '6-10', 'Ris selected from the group consisting of Caryl and 5-10 membered heteroaryl, each of which may be optionally substituted by 1, 2, 3, or 4 independently selected Rgroups;'}{'sup': 1A', 'N1', 'N2', '6, 'sub': 1-6', '1-6', '1-6', '1-6', '6-10', '1-6', '1-6', '6-10, 'each Ris independently selected from the group consisting of halo, Calkyl, Chaloalkyl, Calkoxy, Chaloalkoxy, NRR, and Caryl, wherein the Calkyl, Calkoxy, and Caryl are each optionally substituted by 1, 2, 3, or 4 independently selected Rgroups;'}{'sup': 2', '2A, 'sub': 1-6', '3-6, 'Ris selected from the group consisting of Calkyl, Ccycloalkyl, and phenyl, each of which may be optionally substituted by 1, 2, 3, or 4 independently selected Rgroups;'}{'sup': '3', 'Ris H;'}{'sup': 4', '5, 'Rand Rare each halo; and'}m is 1.6. The method of claim 5 , wherein:{'sup ...

Подробнее
24-01-2019 дата публикации

SYNTHESIS OF CANNABINOIDS

Номер: US20190023680A1
Принадлежит: UNIVERSITY OF SOUTH FLORIDA

Provided are synthesis processes and intermediates for preparing cannabinoids and analogs. 2. The process of claim 1 , wherein step (a) is present.6. The process of claim 2 , wherein step (a) comprises mixing potassium bis(trimethylsilyl)amide (KHMDS) with the compound of formula (II).7. The process of claim 1 , wherein Ris —(CH)-CH.8. The process of claim 1 , wherein Rand Rare —OCH.9. The process of claim 1 , wherein Rand Rare each —CH.10. The process of claim 1 , wherein Ris hydroxyl claim 1 , —CH claim 1 , or —OCH.11. The process of claim 1 , wherein step (b) comprises mixing the compound of formula (III) with (1 claim 1 ,3 -Bi s(2 claim 1 ,4 claim 1 , 6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium.13. The process of claim 12 , wherein Ris C-Calkoxy.14. The process of claim 12 , wherein the cannabinoid is Δ-tetrahydrocannabinol (THC).16. The process of claim 15 , wherein Ris C-Calkyl.17. The process of claim 15 , wherein the cannabinoid is cannabidiol (CBD).19. The compound of claim 18 , wherein Ris —(CH)-CHor —(CH)-CH.21. The compound of claim 20 , wherein Ris —(CH)-CHor —(CH)-CH. This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62/535,388, filed on Jul. 21, 2017, the entire content of which is incorporated herein by reference in its entirety.The present disclosure relates to synthesis methods for cannabinoids and analogues.Cannabinoids are compounds isolated from plants of the genus Cannabis, which are known for their psychotropic properties. There are more than 100 known cannabinoids present in varying amounts depending on the strain of the plant. The cannabinoids exert their physiological properties through their interaction with a series of receptors known as the cannabinoid receptors. Two of the primary cannabinoid receptors are CB1 and CB2, which are expressed in unique quantities in different tissues throughout the body. There is evidence that additional ...

Подробнее
23-01-2020 дата публикации

POGOSTONE DERIVATIVES AND METHODS OF USING THE SAME

Номер: US20200024246A1
Принадлежит: Hamyard Associates LLC

Described are novel derivatives of pogostone and methods of using the same. 2. The pogostone derivative of wherein the structure is selected from a group consisting of Formula 1 claim 1 , Formula 2 claim 1 , Formula 3 claim 1 , Formula 4 claim 1 , Formula 5 claim 1 , Formula 6 claim 1 , Formula 7 claim 1 , Formula 8 claim 1 , Formula 9 claim 1 , Formula 10 claim 1 , Formula 11 claim 1 , Formula 12 claim 1 , Formula 13 claim 1 , Formula 14 claim 1 , Formula 15 claim 1 , Formula 16 claim 1 , Formula 17 claim 1 , Formula 18 claim 1 , Formula 19 claim 1 , Formula 20 claim 1 , Formula 21 claim 1 , Formula 22 claim 1 , Formula 23 claim 1 , Formula 24 claim 1 , Formula 25 claim 1 , Formula 26 claim 1 , Formula 27 claim 1 , Formula 28 claim 1 , Formula 29 claim 1 , Formula 30 claim 1 , Formula 31 claim 1 , Formula 32 claim 1 , Formula 33 claim 1 , Formula 34 claim 1 , Formula 35 claim 1 , Formula 36 claim 1 , Formula 37 claim 1 , Formula 38 claim 1 , Formula 39 claim 1 , Formula 40 claim 1 , Formula 41 claim 1 , Formula 42 claim 1 , Formula 43 claim 1 , Formula 44 claim 1 , Formula 45 claim 1 , Formula 46 claim 1 , Formula 47 claim 1 , and Formula 48.4. The compound of claim 3 , wherein Ra substituted or unsubstituted C-Cunbranched or branched alkyl.5. The compound of claim 3 , wherein Ris a methyl group.6. The compound of claim 3 , wherein Rcomprises a unsubstituted C-Cunbranched or branched cycloalkyl.7. The compound of claim 3 , wherein the compound has the structure of Formula 4 claim 3 , Formula 5 claim 3 , or Formula 9.9. The compound of claim 8 , wherein Ris a substituted or unsubstituted C-Cunbranched or branched alkyl.10. The compound of claim 8 , wherein Ris a hydrogen.11. The compound of claim 8 , wherein X is an oxygen.12. The compound of claim 8 , wherein X is a nitrogen.13. The compound of claim 8 , wherein the compound has the structure of Formula 13 claim 8 , Formula 14 claim 8 , Formula 16 claim 8 , Formula 17 claim 8 , Formula 19 claim 8 , Formula 20 claim ...

Подробнее
29-01-2015 дата публикации

WATER-SOLUBLE FLUORESCENCE COMPOUND AND METHOD FOR PREPARING THE SAME

Номер: US20150031867A1
Принадлежит:

The present invention provides a water-soluble fluorescent compound of resveratrone 6-O-β-glucoside [(E)-4-(8-hydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)naphthalen-2-yl)but-3-en-2-one] and its derivatives of Formula 1 which have at least one water-soluble substituent, and a method for preparing the same by a photochemical reaction of resveratrol 3-O-β-glucoside and its derivatives of having Formula 3 which are not fluorescent. Said new water-soluble fluorescent compounds has single-photon absorptive characteristics and/or two-photon absorptive characteristics as well as no or little toxicity, and can be usefully utilized in fields that requires water-soluble fluorescent characteristics (diagnosis, fluorescent probe, in vivo imaging, display, etc.). 3. The fluorescent compound according to claim 1 , wherein Ris hydrogen atom.5. The method according to claim 4 , characterized in that the compound of Formula 3 is selected from the group consisting of trans-isomer claim 4 , cis-isomer and mixture thereof.6. The method according to claim 4 , characterized in that ascorbic acid claim 4 , polyphenol or mixture thereof is further added before the UV irradiation.7. The method according to claim 4 , characterized in that it is conducted under Natmosphere (Npurging).8. (canceled) The present invention relates to a water-soluble fluorescent compound, a method for preparing the same, and its use.There are cases where light is emitted from a substance at a low temperature at which the substance can not emit any visible ray by thermal radiation. Such lighting phenomenon is referred to as luminescence. Luminescence means the emission of light having a wavelength which correspond to the energy difference when a substance is converted to a stable state having low energy from an unstable state having high energy. Thus, in order to make a substance emit such light, it is necessary to make the substance to an unstable excited state having ...

Подробнее
11-02-2016 дата публикации

COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR

Номер: US20160038641A1
Принадлежит: HUMAN BIOMOLECULAR RESEARCH INSTITUTE

Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes. 1113. The composition of any one of - claims 1 , wherein the isolated cells capable of differentiating into bone cells are isolated human bone marrow-derived mesenchymal stem cells claims 1 , human mesenchymal stem cells of adipose tissue claims 1 , human mesenchymal stem cells of blood claims 1 , human mesenchymal stem cells of bone allograft or autograft tissues claims 1 , human mesenchymal stem cells of dental pulp claims 1 , human pericytes claims 1 , human myoblasts claims 1 , and human chondrocytes claims 1 , human osteoprogenitor cells claims 1 , urine stem cells claims 1 , or their respective progenitor cells such as stem cell isolated from amniotic fluid or cord blood claims 1 , embryonic stem cells claims 1 , and induced pluripotent stem cells.123. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.137. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.14. The composition of compound 8-10 wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.1510. The compositions of any one of - further comprising a calcium phosphate ...

Подробнее
22-02-2018 дата публикации

CYCLOBENZOINS

Номер: US20180050974A1
Автор: Ji Qing, MILJANIC Ognjen
Принадлежит: UNIVERSITY OF HOUSTON SYSTEM

One-step cyanide-catalyzed benzoin condensations for synthesizing shape persistent cyclobenzoin macrocycles. Selected dialdehydes, and cyanide salts are reacted in aqueous solvents to form such cyclobenzoin macrocycles. 2. The method of claim 1 , wherein said solvent is an alcohol.3. The method of claim 2 , wherein said alcohol is selected from the group consisting of 2-methoxyethanol; ethanol; methanol; propanol claim 2 , butanol claim 2 , pentanol isomers claim 2 , and glycols.4. The method of claim 2 , wherein said solvent is in a 1:1 molar ratio with HO.5. The method of claim 1 , wherein said dialdehyde is selected from the group consisting of isophthaldehyde; tetraphthaldehyde; phthaldehyde claim 1 , and aromatic analogs thereof claim 1 , wherein one or more substituted or unsubstituted aromatic or hetoroaromatic rings claim 1 , and/or triple bonds are inserted between two formyl groups.6. The method of wherein said dialdehyde is at a concentration of between 0.1M to 1M.7. The method of claim 5 , wherein said dialdehyde is isophthaldehyde in a concentration of about 0.5M.8. The method of claim 5 , wherein said dialdehyde is tetraphthaldehyde in a concentration of about 0.17M.9. The method of claim 1 , wherein said reacting a dialdehyde and a cyanide salt comprises refluxing under nitrogen gas at a temperature of about 100° C. for about 48 hrs.10. The method of claim 1 , wherein said cyanide salt is selected from the group consisting of NaCN claim 1 , cyanide salts of metals; and thiazolium salts.11. The method of claim 7 , wherein said cyclobenzoin macrocycle is cyclotribenzoin or a cyclotetrabenzoin.12. (canceled)13. The method of claim 1 , wherein said cyclobenzoin macrocycle forms a microporous three-dimensional organic framework claim 1 , or a one dimensional nanotube channel.14. (canceled)15. The method of claim 1 , wherein said cyclobenzoin macrocycle is porous.16. The method of claim 12 , wherein said cyclotetrabenzoin comprises a Langmuir surface area ...

Подробнее
20-02-2020 дата публикации

Sweetness and Taste Improvement of Steviol Glycoside and Mogroside Sweeteners with Dihydrochalcones

Номер: US20200054058A1
Принадлежит:

Compositions and consumables comprising certain sweeteners and at least one dihydrochalcone of Formula I are provided herein, wherein the at least one sweetener is selected from certain steviol glycoside and/or mogroside sweeteners in sweetening amounts. The at least one dihydrochalcone enhances the sweetness of the consumable and optionally modulates one or more taste attributes to make the consumable taste more like a sucrose-sweetened consumable. Methods of enhancing the sweetness of a consumable, methods of making a consumable taste more like a sucrose-sweetened consumable and methods of preparing consumables are also detailed herein. 2. The beverage of claim 1 , wherein the dihydrochalcone is selected from hesperetin dihydrochalcone claim 1 , phloretin claim 1 , neohesperidin dihydrochalcone claim 1 , hesperetin dihydrochalcone-4′-β-D-glucoside and combinations thereof.3. The beverage of claim 1 , wherein the steviol glycoside is selected from the group consisting of rebaudioside M claim 1 , rebaudioside D claim 1 , rebaudioside A claim 1 , rebaudioside N claim 1 , rebaudioside O claim 1 , rebaudioside E claim 1 , steviolmonoside claim 1 , steviolbioside claim 1 , rubusoside claim 1 , dulcoside B claim 1 , dulcoside A claim 1 , rebaudioside B claim 1 , rebaudioside G claim 1 , stevioside claim 1 , rebaudioside C claim 1 , rebaudioside F claim 1 , rebaudioside I claim 1 , rebaudioside H claim 1 , rebaudioside L claim 1 , rebaudioside K claim 1 , rebaudioside J claim 1 , rebaudioside M2 claim 1 , rebaudioside D2 claim 1 , rebaudioside S claim 1 , rebaudioside T claim 1 , rebaudioside U claim 1 , rebaudioside V claim 1 , rebaudioside W claim 1 , rebaudioside Z1 claim 1 , rebaudioside Z2 claim 1 , rebaudioside IX claim 1 , enzymatically glucosylated steviol glycosides and combinations thereof.4. The beverage of claim 1 , wherein the mogroside is selected from the group consisting of grosmogroside I claim 1 , mogroside IA claim 1 , mogroside IE claim 1 , 11- ...

Подробнее
27-02-2020 дата публикации

Anti-Inflammatory Composition

Номер: US20200062684A1
Принадлежит:

It is an object of the present invention to provide a composition having an anti-inflammatory action. The present invention relates to an anti-inflammatory composition, a prostaglandin E2 production inhibitory composition, and a nitric oxide production inhibitory composition, which are useful as food or beverage or pharmaceutical products.The present invention also relates to a novel compound having a prostaglandin E2 production inhibitory activity and a nitric oxide production inhibitory activity.Prostaglandin E2 (PGE2) is generated in leukocytes (macrophages), mast cells, endothelial cells, platelets and the like. Arachidonic acid existing as a structural component of a cell membrane phospholipid is cleaved by phospholipase, and is passed through a cyclooxygenase pathway, thereby synthesizing PGE2. In the process of inflammation, the aforementioned pathway is activated, and generation of PGE2 is thereby increased.PGE2 released from specific cells acts on target cells present in the vicinity thereof, and induces an inflammatory reaction in the target cells. PGE2 is one chemical mediator for amplifying an inflammatory reaction in an inflamed site, and activates the inflammatory reaction in the inflamed site.Nitric oxide (NO) is generated in the process of inflammation by type II nitric oxide synthase (iNOS) of leukocytes (macrophages) induced by an inflammatory cytokine or bacterial endotoxin (Non Patent Literature 1). Excessively generated NO is converted to peroxynitrous acid, which then exhibits a cytotoxic action such as DNA damage or LDL oxidation (Non Patent Literature 2). Thus, it is important to suppress excessive generation of NO due to inflammation. In addition, since NO activates an intracellular signal pathway for promoting inflammation, such as an NF-κB pathway (Non Patent Literature 3), suppression of NO generation is also important for exhibiting an anti-inflammatory action (Patent Literature 1).Inflammation is provoked by stimulating factors such as ...

Подробнее
26-03-2015 дата публикации

Protective Effects of Curcumin Against Hemorrhagic Stroke Injury

Номер: US20150087705A1
Принадлежит:

Disclosed herein are compounds, compositions and methods for preventing and treating diseases such as intracerebral hemorrhage, cancer, or conditions associated with damaged cells, activated lymphocytes, or microbial products. The disclosed compounds are curcumin analogs. The curcumin analogs possess anti-inflammatory and antioxidant properties, which in part, reduce AP-1 and NF-κB activity. 2. A compound of claim 1 , wherein{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10, 'R, R, R, R, R, R, R, R, R, and Rare independently selected from the group consisting of hydrogen, alkyl, halogen, alkoxy, carboxyl, alkoxycarbonyl, haloalkyl, haloalkloxy, and haloalkylamino, and'}{'sub': '11', 'Ris independently selected from the group consisting of hydrogen, alkyl, halogen, alkoxy, carboxyl, alkoxycarbonyl, ester, and alkyl ester.'}3. A compound according to claim 1 , wherein{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '1', '4, 'R, R, R, R, R, R, R, R, Rand Rare independently selected from the group consisting of hydrogen, alkyl, halogen, and C-Calkoxy, and'}{'sub': '11', 'Ris selected from the group consisting of hydrogen, alkyl, alkoxy, carboxyl, alkoxycarbonyl, ester, and alkyl ester.'}5. A pharmaceutical composition comprising one or more of the compounds claim 1 , pharmaceutically acceptable salt claim 1 , prodrug claim 1 , clathrate claim 1 , tautomer or solvate thereof according to and a pharmaceutically acceptable excipient.6. The composition of claim 5 , wherein the one or more compounds are present in an effective amount to reduce the expression of proinflammatory mediators claim 5 , tumor necrosis factor-α claim 5 , interleukin-6 claim 5 , or interleukin-1β.7. The composition of claim 5 , wherein the one or more compounds are present in an effective amount to reduce disruption of the blood-brain barrier.8. The composition of claim 5 , wherein the one or more compounds are present in an effective amount to increase neurological outcome scores ...

Подробнее
31-03-2022 дата публикации

MOISTURE-CURABLE POLYOLEFIN FORMULATION

Номер: US20220098432A1
Принадлежит:

A moisture-curable polyolefin formulation comprising a (hydrolyzable silyl group)-functional polyolefin prepolymer and a condensation-cure catalyst system comprising and/or made from mixture of a compound that is a carboxamidine or a guanidine and a compound that is a cobalt acetylacetonate or a zinc acetylacetonate, wherein each compound independently is unsubstituted or substituted. Also, methods of making and using same, a cured polyolefin made therefrom, and articles containing or made from same. Also, condensation-cure catalyst systems useful therein. 1. A moisture-curable polyolefin formulation comprising:(A) a (hydrolyzable silyl group)-functional polyolefin prepolymer; and{'sub': ['2', '3', '2'], '#text': '(B) a condensation-cure catalyst system comprising a mixture made by contacting a compound that is a carboxamidine or a guanidine and is unsubstituted or substituted (collectively called “(aza)carboxamidine”) with a compound that is a cobalt acetylacetonate coordination complex or a zinc acetylacetonate coordination complex, wherein each acetylacetonate independently is unsubstituted or substituted with from 1 to 5 alkyl groups, wherein each alkyl group is unsubstituted (collectively called “Co,Zn (alkyl)acetylacetonate”); wherein the Co,Zn (alkyl)acetylacetonate is selected from a cobalt(II) ((alkyl)acetylacetonate), a cobalt(III) ((alkyl)acetylacetonate), and a zinc(II) ((alkyl)acetylacetonate);'}wherein the amount of (A) is from 79.0 to 99.99 weight percent (wt %) and the amount of (B) is from 21.0 to 0.01 wt %, respectively, of the moisture-curable polyolefin formulation; andwherein the (B) condensation-cure catalyst system is characterized by an (aza)carboxamidine/Co,Zn (alkyl)acetylacetonate molar ratio of from 15 to 0.15.2. The moisture-curable polyolefin formulation of wherein the (A) (hydrolyzable silyl group)-functional polyolefin prepolymer is characterized by any one of limitations (i) to (iii): (i) each hydrolyzable silyl group is ...

Подробнее
12-03-2020 дата публикации

Sacubitril intermediate and preparation method thereof

Номер: US20200079721A1

The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril.

Подробнее
02-04-2020 дата публикации

MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT

Номер: US20200102264A1
Принадлежит: The University of Kansas

A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colo-rectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds. 2. The compound of claim 1 , wherein:{'sup': '2', 'Rincludes one or more of a hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, thios, sulfhydryls, phosphors, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, derivatives thereof, substituted or unsubstituted, or combinations thereof.'}3. The compound of claim 1 , wherein Rincludes one or more of hydrogen claim 1 , C-Calkyl claim 1 , C-Calkenyl claim 1 , C-Calkynyl claim 1 , C-Caryl claim 1 , C-Calkaryl claim 1 , C-Caralkyl claim 1 , halo claim 1 , hydroxyl claim 1 , sulfhydryl claim 1 , C-Calkoxy claim 1 , C-Calkenyloxy claim 1 , C-Calkynyloxy claim 1 , C-Caryloxy claim 1 , acyl claim 1 , C-Calkylcarbonyl (—CO-alkyl) claim 1 , C-Carylcarbonyl (—CO-aryl) claim 1 , acyloxy (—O-acyl) claim 1 , C- ...

Подробнее
13-05-2021 дата публикации

COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR

Номер: US20210138117A1
Принадлежит: HUMAN BIOMOLECULAR RESEARCH INSTITUTE

Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, trans-differentiation, and proliferation of animal cells into the osteoblast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes. 11. The composition of any one of - , wherein the isolated cells capable of differentiating into bone cells are isolated human bone marrow-derived mesenchymal stem cells , human mesenchymal stem cells of adipose tissue , human mesenchymal stem cells of blood , human mesenchymal stem cells of bone allograft or autograft tissues , human mesenchymal stem cells of dental pulp , human pericytes , human myoblasts , and human chondrocytes , human osteoprogenitor cells , urine stem cells , or their respective progenitor cells such as stem cell isolated from amniotic fluid or cord blood , embryonic stem cells , and induced pluripotent stem cells.12. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.13. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.14. The composition of compound 8-10 wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.15. The compositions of any one of - further comprising a calcium phosphate matrix , wherein the compound is covalently associated onto the calcium phosphate matrix.16. The compositions of any one of - ...

Подробнее
13-05-2021 дата публикации

NOVEL BENZYLIDENEACETONE DERIVATIVE AND USE THEREOF

Номер: US20210139414A1
Принадлежит:

The present invention relates to novel benzylideneacetone derivatives or uses thereof, more specifically, the present invention relates to a pharmaceutical composition for preventing or treating, or food composition for ameliorating a cancer or a bone disease comprising a compound defined by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. 2. The compound defined by Formula 1 or a pharmaceutically acceptable salt thereof of claim 1 , wherein R1 is one selected from the group consisting of —OH claim 1 , methyl claim 1 , methoxy claim 1 , —F claim 1 , and —SH;{'sub': 1-4', '1-4, 'R2 is one selected from the group consisting of —OH, —SH, Cstraight or branched alkyl, Cstraight or branched alkoxy, halogen, allyloxy, benzyloxy, aryloxy having one or more selected from the group consisting of hetero atoms and substituents, and heterocycloalkyl of 3 to 7 atoms having one or more hetero atoms, wherein the hetero atoms consist of O, N and S;'}{'sub': '2', 'R3 is methyl or —NH.'}3. The compound defined by Formula 1 or a pharmaceutically acceptable salt thereof of claim 2 , wherein the compound defined by Formula 1 is selected from the group consisting of the following compounds:(1) (E)-4-(3-hydroxy-4-methylphenyl)but-3-en-2-one;(2) (E)-4-(4-fluoro-3-hydroxyphenyl)but-3-en-2-one;(3) (E)-4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one;(4) (E)-4-(3-hydroxy-4-methoxyphenyl)-3-buten-2-one;(5) (E)-4-(3-fluoro-4-hydroxyphenyl)-3-buten-2-one;(6) (E)-3-(3-hydroxy-4-methylphenyl)acrylamide;(7) (E)-3-(4-fluoro-3-hydroxyphenyl)acrylamide;(8) (E)-4-(4-mercapto-3-hydroxyphenyl)but-3-en-2-one;(9) (E)-4-(4-hydroxy-3-mercaptophenyl)but-3-en-2-one;(10) (E)-4-(3-hydroxy-4-isopropoxyphenyl)but-3-en-2-one;(11) (E)-4-(4-(benzyloxy)-3-hydroxyphenyl)but-3-en-2-one;(12) (E)-4-(4-(allyloxy)-3-hydroxyphenyl)but-3-en-2-one;(13) (E)-4-(3-hydroxy-4-(4-methylpiperazine-1-yl)phenyl)but-3-en-2-one;(14) (E)-4-(3-hydroxy-4-(pyrrolidine-1-yl)phenyl)but-3-en-2-one;{'img': {'@id': 'CUSTOM ...

Подробнее
02-05-2019 дата публикации

Aryl beta diketones and their use as odorants

Номер: US20190127305A1
Принадлежит: Givaudan SA

The present invention refers to aryl beta diketones of the formula (I) wherein Y, R 1 , R 2 and R 3 have the meaning R 1 is selected from the group consisting of hydrogen, C 1 -C 4 alkyl, hydroxyl, methoxy, CF 3 and F; R 2 is selected from the group consisting of methyl and ethyl; R 3 is selected from the group consisting of methyl and ethyl; and Y is a bivalent residue selected from the group consisting of —C(O)—; —CH 2 ═CH 2 —C(O)—; —CR I R II —C(O)—, wherein R I and R II are independently selected from hydrogen and methyl; and —CHR III —CHR IV —C(O)—, wherein R III and R IV are independently selected from hydrogen and methyl with the proviso, that R III ═R IV are hydrogen or either R III or R IV is methyl. The invention further refers to fragrance compositions and fragranced articles comprising them.

Подробнее
25-05-2017 дата публикации

MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT

Номер: US20170144965A1
Принадлежит:

A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colorectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds. 2. The compound of claim 1 , wherein:{'sup': 1', '2', '3', '4', '5, 'at least one of R, R, R, or R, or Rindependently includes one or more of a hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, thios, sulfhydryls, phosphors, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, derivatives thereof, substituted or unsubstituted, or combinations thereof.'}3. The compound of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , or Rindependently includes one or more of hydrogen claim 1 , C-Calkyl claim 1 , C-Calkenyl claim 1 , C-Calkynyl claim 1 , C-Caryl claim 1 , C-Calkaryl claim 1 , C-Caralkyl claim 1 , halo claim 1 , hydroxyl claim 1 , sulfhydryl claim 1 , C-Calkoxy claim 1 , C-Calkenyloxy claim 1 , C-Calkynyloxy claim 1 ...

Подробнее
15-09-2022 дата публикации

COMPOSITION FOR PREVENTING OR TREATING BACTERIAL INFECTIOUS DISEASE COMPRISING 4-GINGEROL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT

Номер: US20220289657A1
Принадлежит:

The present invention relates to a 4-gingerol derivative compound, or a racemate, isomer, or pharmaceutically acceptable salt thereof, the compound being capable of inhibiting biofilm formation and production of virulence factors. The 4-gingerol derivative compound according to the present invention has binding affinity to RhlR and corresponding RhlR antagonism activity that are significantly improved, and therefore can effectively inhibit biofilm formation and production of virulence factors. Furthermore, various bacterial infectious diseases caused by biofilms can be fundamentally prevented or treated by using a pharmaceutical composition comprising the 4-gingerol derivative compound, or a racemate, isomer, or pharmaceutically acceptable salt thereof as an active ingredient. 4. The compound of claim 3 , wherein the gingerol derivative compound represented by Formula 2 is any one selected from combinations of X claim 3 , Y claim 3 , and Z:(1) X═OMe, Y═OH, Z═H(2) X═H, Y═H, Z═H(3) X═OMe, Y═H, Z═H(4) X═H, Y═OH, Z═H(5) X═OH, Y═H, Z═H(6) X═H, Y═OMe, Z═H(7) X═H, Y═F, Z═H(8) X═H, Y═Cl, Z═H(9) X═H, Y=Me, Z═H{'sub': '2', '(10) X═H, Y═NMe, Z═H'}(11) X═OH, Y═OH, Z═H(12) X═OMe, Y═OMe, Z═H(13) X═F, Y═OH, Z═H(14) X═OEt, Y═OH, Z═H(15) X═F, Y═F, Z═H(16) X=Me, Y=Me, Z═H(17) X═OMe, Y═F, Z═H(18) X═F, Y═H, Z═OMe5. The compound of claim 1 , which inhibits biofilm formation and virulence factor production.6Pseudomonas aeruginosa, SalmonellaShigellaVibrio parahaemolyticus, Vibrio choreae, Escherichia coliCampylobacter jejuni, Clostridium difficile, Clostridium perfringens, Yersinia enterocolitica, Helicobacter pylori, Entemoeba histolytica, Bacillusu cereus, Clostridium botulinum, Haemophilus influenzae, Streptococcus pneumoniae, Chlamidia pneumoniae, Legionella pneumoniae, Branhamella catarrhalis, Mycobacterium tuberculosis, Mycoplasma pneumoniaeStreptococcusStreptococcus pyogenesCorynebacterium diphtheriae, Bordetella pertussis, Chramidia psittaciStaphylococcus aureusEscherichia coli, ...

Подробнее
31-05-2018 дата публикации

PHENOL DERIVATIVES TO TREAT CANCER

Номер: US20180148427A1

The present invention relates to compounds of general formula (I) 115-. (canceled)19. The compound according to claim 16 , wherein Ris hydrogen.20. The compound according to claim 16 , wherein Ris hydrogen or chloro.21. The compound according to claim 16 , wherein Ris hydrogen and Ris CHO.22. The compound according to claim 16 , wherein Ris hydrogen.23. The compound according to claim 16 , wherein hydroxyl protecting groups for R claim 16 , R claim 16 , R claim 16 , R claim 16 , R claim 16 , R claim 16 , R claim 16 , Rand Rare independently selected from the group consisting of:ethers of formula —R′;esters of formula —C(═O)R′; andcarbonates of formula —C(═O)OR′;wherein R′ can be independently selected from the group consisting of substituted or unsubstituted alkyl and substituted or unsubstituted aryl.27. A method for the manufacture of a medicament comprising the step of combining a compound of formula (I) as defined for the pharmaceutical composition of or a pharmaceutically acceptable salt claim 25 , stereoisomer or solvate thereof claim 25 , with a pharmaceutically acceptable excipient.28. A method for the treatment and/or prophylaxis of cancer claim 25 , the method comprising administering to the subject in need of such a treatment or prophylaxis an effective amount of a compound of formula (I) as defined for the pharmaceutical composition of or a pharmaceutically acceptable salt claim 25 , stereoisomer or solvate thereof.31. The method according to claim 29 , wherein the compound of formula (I) meets at least one of the following conditions (a) to (d):{'sup': '3', '(a) Ris hydrogen;'}{'sup': '5', '(b) Ris hydrogen or chloro;'}{'sup': 6', '7, '(c) Ris hydrogen and Ris CHO; and'}{'sup': '8', '(d) Ris hydrogen.'}32. The method according to claim 30 , wherein the compound of formula (I) meets at least one of the following conditions (a) to (d):{'sup': '3', '(a) Ris hydrogen;'}{'sup': '5', '(b) Ris hydrogen or chloro;'}{'sup': 6', '7, '(c) Ris hydrogen and Ris CHO; ...

Подробнее
18-06-2015 дата публикации

DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR

Номер: US20150166498A1
Принадлежит: NAI INC.

The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor which is applicable to various diseases. When used as an active ingredient, a compound represented by formula (I): 2. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , whereinX represents a chlorine atom,{'sup': '2', 'Rrepresents a methyl group, and'}{'sup': 4', '0', '0, 'sub': 2', '3', '3', '3', '3', '2', '3', '2', '3', '3', '2', '3', '3', '3', '3', '3', '3', '3, 'Rrepresents —CH—CH═C(CH)—R(wherein Rrepresents an alkyl group containing 1 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon, or an alkenyl group containing 2 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon), provided that when Ro has a substituent, the substituent is selected from the group consisting of —O—CO—C(CH), —O—CO—CH(CH), —C(CH)—O—CH, —O-(2-furyl), —OH, —CH(OCH)—CH—CO—C(CH), —CHO, —CO—O—CH, —CO—CH, —O—CO—CHand —CO—C(CH).'}4. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , which comprises glycerol.5. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , which is used as an immunosuppressive agent.6. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , which is used as a therapeutic agent for rheumatism.7. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , which is used as an anticancer agent.8. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , which is used as a therapeutic agent for graft rejection in organ transplantation.9. The dihydroorotic acid dehydrogenase inhibitor according claim 1 , which is used as a therapeutic agent for diabetes.10. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , which is used as an antiviral agent.11H. pylori. The dihydroorotic acid dehydrogenase inhibitor according to claim 1 , which is used as an anti-agent.13. The kit according to claim 12 , ...

Подробнее
05-07-2018 дата публикации

PLANT GROWTH PROMOTERS AND METHODS OF USING THEM

Номер: US20180184651A1
Автор: AL-BABILI Salim
Принадлежит:

New plant growth regulators, including compounds and compositions, and methods of use including for promoting root growth. The compounds are carotenoid oxidation products, and a preferred example is 3-OH-β-apo-13-Carotenone. A method comprising promoting the growth of at least one plant with use of an effective amount of at least one composition comprising an effective amount of at least one compound which is represented by A-B-C, wherein B is a bivalent polyene moiety, A is a monovalent moiety linked to B by a six-membered carbon ring, wherein the ring has at least one substituent linked to the ring by an oxygen atom, and C is a monovalent moiety linked to B by a carbonyl group. Synergistic effects can be used with combinations of compounds. 1. A method comprising promoting the growth of at least one plant with use of an effective amount of at least one composition comprising an effective amount of at least one compound which is represented by A-B-C , wherein B is a bivalent polyene moiety , A is a monovalent moiety linked to B by a six-membered carbon ring , wherein the ring has at least one substituent linked to the ring by an oxygen atom , and C is a monovalent moiety linked to B by a carbonyl group.2. The method of claim 1 , wherein the bivalent polyene moiety B is a C-Chydrocarbon moiety with no heteroatoms.3. The method of claim 1 , wherein the bivalent polyene moiety B has three conjugated double bonds.4. The method of claim 1 , wherein the double bonds of bivalent polyene moiety B are in an all trans configuration.6. The method of claim 1 , wherein the six-membered ring is a phenyl ring claim 1 , a cyclohexane ring claim 1 , a cyclohexadiene ring claim 1 , or a cyclohexene ring.7. The method of claim 1 , wherein the six-membered ring is an unsaturated ring.8. The method of claim 1 , wherein monovalent moiety A consists of only one cyclohexene ring.9. The method of claim 1 , wherein monovalent moiety A comprises a cyclohexene ring claim 1 , and the ...

Подробнее
04-08-2016 дата публикации

MTOR-independent activator of TFEB for autophagy enhancement and uses thereof

Номер: US20160221907A1
Принадлежит:

The present invention relates to a composition comprising an autophagy enhancement compound. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed. 6. The method according to claim 5 , wherein the neurodegenerative diseases comprising Alzheimer's disease claim 5 , Parkinson's disease claim 5 , Huntington's disease and Creutzfeldt-Jakob disease.12. A method of enhancing lysosome biogenesis in cells comprising providing the mono-carbonyl analog of .13. The method of claim 12 , wherein the cells are neuronal cells.14. The method of claim 12 , wherein the cells are non-neuronal cells.16. The method according to wherein said mono-carbonyl analog of curcumin is administered to the subject in need thereof via oral administration.17. The method according to wherein said cells are neuronal cells. This application is a continuation-in-part application of the U.S. non-provisional patent application Ser. No. 14/609,438 filed Jan. 30, 2015, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/949,233 filed on Mar. 6, 2014, the disclosures are hereby incorporated by reference in their entirety.The present invention relates to a composition comprising an autophagy enhancement compound. In particular, the present invention relates to a composition comprising a small molecule being able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's diseases.Macroautophagy, herein referred to as autophagy, is a highly conserved process for cellular degradation and recycling of cytosolic contents to maintain cellular homeostasis. Autophagy substrates are generally cellular organelles, long-lived proteins and aggregate-prone proteins. Due to ...

Подробнее
18-07-2019 дата публикации

PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS

Номер: US20190218181A1
Принадлежит:

The present invention relates to a process for the manufacture of hydroxy-substituted aromatic styryl or stilbene compounds. 2. The process according to claim 1 , wherein Z is a divalent substituted aromatic group.3. The process according to claim 1 , wherein the compound of formula (III) is formed in situ from a compound of formula (IV){'br': None, 'HOOC—CH═CH—Ar \u2003\u2003(IV),'}wherein Ar is as defined above.4. The process according to claim 1 , wherein the transition metal catalyst is a bimetallic catalyst comprising palladium and at least one further transition metal.5. The process according to claim 1 , wherein the leaving group X is a halogenide.6. The process according to claim 1 , wherein Z is derived from a substituted six-membered aromatic group.7. The process according to claim 1 , wherein Z is derived from a hydroxy-substituted benzene group and/or Ar is derived from a hydroxyl-substituted benzene group.8. The process according to claim 1 , wherein each group Ar is derived from a hydroxy-substituted benzene group.11. The process according to claim 1 , which is carried out in at least one solvent claim 1 , and in the presence of at least one base.12. The process according to comprising adding water to the process.13. The process according to claim 1 , which is carried out in the presence of at least one phase transfer catalyst compound.14. The process according to claim 13 , which is carried out in the absence of triphenylphosphane.15. The process according to claim 1 , which further comprises at least one subsequent derivatization reaction of the compound of formula (I).16. The process according to claim 1 , which further comprises the admixture of a compound of formula (1) with at least one pharmaceutical or cosmetic excipient.17. The process according to claim 4 , wherein the at least one further transition metal comprises copper or silver.18. The process according to claim 5 , wherein the halogenide is chlorine or bromine.19. The process according ...

Подробнее
31-08-2017 дата публикации

O-PHENYL CHALCONE COMPOUNDS AND USES THEREOF

Номер: US20170247398A1
Принадлежит: SUN YAT-SEN UNIVERSITY

Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and has a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations. 3. Use of the o-phenyl chalcone compounds of in the preparation of the anti-tumor drugs.4. Use of the o-phenyl chalcone compounds of in the preparation of drugs against drug-resistant tumors.5. The Use of claim 4 , wherein the drug-resistant tumors include but not limited to paclitaxel- claim 4 , vinblastine- claim 4 , doxorubicin- and cisplatin-resistant tumors.6. The Use of any of claim 3 , wherein the tumors include but not limited to breast cancers claim 3 , lung cancers claim 3 , colon cancers claim 3 , nasopharyngeal carcinomas and liver cancers.7. Use of the pharmaceutically acceptable salts of in the preparation of the anti-tumor drugs.8. Use of the pharmaceutically acceptable salts of in the preparation of drugs against drug-resistant tumors.9. The Use of claim 8 , wherein the drug-resistant tumors include but not limited to paclitaxel- claim 8 , vinblastine- claim 8 , doxorubicin- and cisplatin-resistant tumors.10. The Use of any of claim 7 , wherein the tumors include but not limited to breast cancers claim 7 , lung cancers claim 7 , colon cancers claim 7 , nasopharyngeal carcinomas and liver cancers. The present application is a continuation of U.S. patent application Ser. No. 15/218,738, filed Jul. 25, 2016, which is a continuation of International Application No. PCT/CN2015/070651 filed Jan. 14, 2015, which claims ...

Подробнее
27-09-2018 дата публикации

MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT

Номер: US20180273469A1
Принадлежит:

A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colo-rectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds. 2. The compound of claim 1 , wherein:{'sup': 1', '2, 'Ror Reach independently includes one or more of a hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, thios, sulfhydryls, phosphors, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, derivatives thereof, substituted or unsubstituted, or combinations thereof.'}3. The compound of claim 1 , wherein Ror Reach independently includes one or more of hydrogen claim 1 , C-Calkyl claim 1 , C-Calkenyl claim 1 , C-Calkynyl claim 1 , C-Caryl claim 1 , C-Calkaryl claim 1 , C-Caralkyl claim 1 , halo claim 1 , hydroxyl claim 1 , sulfhydryl claim 1 , C-Calkoxy claim 1 , C-Calkenyloxy claim 1 , C-Calkynyloxy claim 1 , C-Caryloxy claim 1 , acyl claim 1 , C-Calkylcarbonyl (—CO-alkyl) claim 1 , C-Carylcarbonyl (—CO ...

Подробнее
25-11-2021 дата публикации

NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Номер: US20210363121A1
Принадлежит:

Compounds of formula (I) in the capacity of compounds with anti-tumor activity for the treatment of T-cell acute lymphoblastic leukemia (T-ALL). 110.-. (canceled)12. The inhibitor of Notch signaling of formula (I) according to claim 11 , wherein X and Y are carbon atoms bound by a double bond having claim 11 , independently claim 11 , an E or Z configuration.13. The inhibitor of Notch signaling of formula (I) according to claim 11 , wherein{'sub': 1′', 'A', 'A', 'A', '2', 'A', '3', 'A', '2', 'A', '3', 'A', 'A', '3, 'R is hydrogen, halogen, OR, OC(═O)R, SR, SOR, SOR, OSOR, OSOR, C(R);'}{'sub': 2′', '3′', '1', '2', '3', 'B', 'B', 'B', 'B', 'B', '2', 'B', '3', 'B', '2', 'B', '3', 'B', 'B', '2', 'B', 'B', '2', 'B', '3, 'R, R, R, R, Rare the same or different and independently selected from: hydrogen; halogen; OR; C(═O)R; C(═O)OR; OC(═O)R; SR; SOR; SOR; OSOR; OSOR; N(R); NHC(═O)R; C(═O)N(R); C(R);'}{'sub': A', 'B', '1-7', '5-7', '5-7, 'at each occurrence, Rand Rare independently selected from: hydrogen; a linear or branched, saturated or unsaturated Caliphatic group optionally containing up to three heteroatoms independently selected from nitrogen, oxygen and sulfur; a Ccycloalkyl group; a phenyl group; a Cheterocyclic group;'}14. The inhibitor of Notch signaling of formula (I) according to claim 11 , wherein{'sub': 1′', 'A', 'A', 'A', '2', 'A', '3', 'A', '2', 'A', '3', 'A', 'A', '3, 'R is hydrogen, halogen, OR, OC(═O)R, SR, SOR, SOR, OSOR, OSOR, C(R);'}{'sub': 2′', '3′', '1', '2', '3', '1-7', '5-7', '5-7, 'R, R, R, R, Rare the same or different and independently selected from: a linear or branched, saturated or unsaturated Cacyclic aliphatic group optionally containing up to three heteroatoms independently selected from nitrogen, oxygen or sulfur; a Ccycloalkyl group; a phenyl group; a Cheterocyclic group; and'}{'sub': 'A', 'claim-ref': {'@idref': 'CLM-00011', 'claim 11'}, 'Rhas the meaning indicated in .'}15. The inhibitor of Notch signaling of formula (I) according to ...

Подробнее
18-12-2014 дата публикации

Treatment of cancer, inflammatory disease, and autoimmune disease

Номер: US20140371177A1
Принадлежит: AndroScience Corp

A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.

Подробнее
10-09-2020 дата публикации

GINGEROL DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST BIOFILM FORMATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING BIOFILM-CAUSED INFECTION SYMPTOM

Номер: US20200283364A1
Принадлежит:

The present invention relates to a gingerol derivative having inhibitory activity against biofilm formation and a pharmaceutical composition for preventing or treating infections caused by biofilms including the gingerol derivative as an active ingredient. The gingerol derivative of the present invention exhibits significantly improved binding affinity for LasR and inhibitory activity against biofilm formation. Therefore, the gingerol derivative of the present invention can act on various membrane surfaces where biofilms tend to form and can effectively inhibit the formation of the corresponding biofilms. In addition, the use of the pharmaceutical composition according to the present invention can fundamentally prevent or treat a variety of infections caused by biofilms due to the presence of the gingerol derivative in the pharmaceutical composition. 3. The gingerol derivative according to claim 1 , wherein the gingerol derivative inhibits biofilm formation.4Pseudomonas aeruginosa, SalmonellaShigellaVibrio parahaemolyticus, Vibrio choreae, Escherichia coliCampylobacter jejuni, Clostridium difficile, Clostridium perfringens, Yersinia enterocolitica, Helicobacter pylori, Entemoeba histolytica, Bacillusu cereus, Clostridium botulinum, Haemophilus influenzae, Streptococcus pneumoniae, Chlamidia pneumoniae, Legionella pneumoniae, Branhamella catarrhalis, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Storeptcoccus pyogenes, Corynebacterium diphtheriae, Bordetella pertussis, Chramidia psittaci,Staphylococcus aureusEscherichia coli, Klebsiella pneumoniae, EnterobacterProteusAcinetobacterEnterococcus faecalis, Staphylococcus saprophyticusStoreptcoccus agalactiae.. The gingerol derivative according to claim 3 , wherein the biofilm is formed by one or more bacterial species selected from the group consisting of spp. claim 3 , spp. claim 3 , O-157 claim 3 , methicillin resistant (MRSA) claim 3 , spp. claim 3 , spp. claim 3 , spp. claim 3 , claim 3 , and5. A composition for ...

Подробнее
17-09-2020 дата публикации

BISACURONE EXTRACTION METHOD

Номер: US20200288761A1
Принадлежит:

It is an object of the present invention to provide a novel means for purifying bisacurone from turmeric at low costs and in a high concentration.

Подробнее
24-09-2020 дата публикации

SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,1'-BIPHENYL COMPOUNDS

Номер: US20200299253A1
Принадлежит:

Provided herein are substituted 1,2,3,4-tetrahydro-1,1′-biphenyl compounds and methods of making same. 2. The compound of claim 1 , wherein Ris —(CH)—CHor —(CH)—CH.4. The compound of claim 3 , wherein Ris —(CH)—CHor —(CH)—CH.6. The process of claim 5 , wherein step (a) is present.10. The process of claim 6 , wherein step (a) comprises mixing potassium bis(trimethylsilyl)amide (KHMDS) with the compound of formula (II).11. The process of claim 5 , wherein Ris —(CH)—CH.12. The process of claim 5 , wherein Rand Rare —OCH.13. The process of claim 5 , wherein Rand Rare each —CH.14. The process of claim 5 , wherein Ris hydroxyl claim 5 , —CH claim 5 , or —OCH.15. The process of claim 5 , wherein step (b) comprises mixing the compound of formula (III) with (1 claim 5 ,3-Bis(2 claim 5 ,4 claim 5 ,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium. This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62/535,388, filed on Jul. 21, 2017; and U.S. Utility application Ser. No. 16/024,368, filed on Jun. 29, 2018, the entire contents of which is incorporated herein by reference in its entirety.The present disclosure relates to synthesis methods for cannabinoids and analogues.Cannabinoids are compounds isolated from plants of the genus , which are known for their psychotropic properties. There are more than 100 known cannabinoids present in varying amounts depending on the strain of the plant. The cannabinoids exert their physiological properties through their interaction with a series of receptors known as the cannabinoid receptors. Two of the primary cannabinoid receptors are CB1 and CB2, which are expressed in unique quantities in different tissues throughout the body. There is evidence that additional cannabinoid receptors exist, including GPR18 and GPR55. The overall biological response to use is a composite of the interaction of the various cannabinoids with each of these receptors, such ...

Подробнее
10-10-2019 дата публикации

PRODUCTION OF FRAMBINONE BY A RECOMBINANT FUNGAL MICROORGANISM

Номер: US20190309330A1
Принадлежит:

The invention relates to a genetically modified fungal microorganism for the production of frambinone, said microorganism having the following characteristics: —the capacity to produce frambinone from tyrosine; and —a limited capacity or no capacity to break tyrosine down into tyrosol, p-hydroxyphenylacetaldehyde and/or p-hydroxyphenylacetate; and to the use of same for producing frambinone. 1. A genetically modified fungal microorganism for the production of frambinone , said microorganism having the following characteristics:a capacity to produce frambinone from tyrosine; anda limited capacity or no capacity to break tyrosine down into tyrosol, p-hydroxyphenylacetaldehyde and/or p-hydroxyphenylacetate.2. The microorganism according to characterized in that the microorganism belongs to the phyla ascomycetes or basidiomycetes.3. The microorganism of characterized in that the microorganism includes at least one heterologous sequence encoding the enzyme 4-coumarate: CoA ligase (4CL) or benzalacetone synthase (BAS).4. The microorganism according to characterized in that the microorganism additionally comprises at least one heterologous or supernumerary sequence encoding the enzyme tyrosine ammonia lyase (TAL) or benzalacetone reductase (BAR).5. The microorganism according to characterized in that the microorganism additionally comprises at least one heterologous or supernumerary sequence encoding the enzyme phenylalanine ammonia lyase (PAL) or cinnamate 4 hydroxylase (C4H).6. The microorganism according to characterized in that the microorganism has hydroxyphenyl pyruvate decarboxylase (HPPDC) activity less than or equal to 2×10−6 kat per g of protein.7. The microorganism according to characterized in that the microorganism comprises at least one mutation or deletion in at least one of the genes encoding the following enzymes: deaminase Aro8 claim 6 , deaminase Aro9 claim 6 , decarboxylase Aro10 claim 6 , decarboxylase Pdc5 claim 6 , decarboxylase Pdc6 claim 6 , or ...

Подробнее
30-11-2017 дата публикации

CATALYTIC OXIDATION OF BUT-3-ENE-1,2-DIOL

Номер: US20170342029A1
Принадлежит:

The invention concerns a synthesis process of a compound of the following formula (I) or one of the salts thereof, 2. The process according to claim 1 , wherein the active phase consists of palladium or of a mixture of palladium and at least one noble metal selected from platinum and gold.3. The process according to claim 1 , wherein the active phase consists of a noble metal or a mixture of noble metals in a content ranging from 0.005 to 50% by weight relative to the weight of the support in the oxide form.4. The process according to claim 1 , wherein the support comprises at least one of hydrotalcites (HT) claim 1 , brucites claim 1 , hydroxyapatite Ca(PO)(OH) claim 1 , tricalcium phosphate Ca(PO) claim 1 , calcium hydrogenphosphate CaHPO(0-2)HO claim 1 , calcium diphosphate CaPO claim 1 , octacalcium phosphate CaH(PO).5HO claim 1 , tetracalcium phosphate Ca(PO)O claim 1 , amorphous calcium phosphates Ca(PO).nHO claim 1 , oxides claim 1 , hydroxides claim 1 , carbonates claim 1 , bicarbonates claim 1 , phosphates claim 1 , diphosphates claim 1 , and calcium hydrogenphosphates claim 1 , cesium claim 1 , lithium claim 1 , rubidium claim 1 , potassium claim 1 , magnesium claim 1 , barium claim 1 , cerium claim 1 , lanthanum claim 1 , aluminum claim 1 , zinc claim 1 , copper claim 1 , and mixtures thereof.6. The process according to claim 1 , wherein the catalyst comprises a promoter selected from bismuth claim 1 , lead claim 1 , antimony claim 1 , tin claim 1 , niobium claim 1 , tellurium claim 1 , indium claim 1 , gallium claim 1 , zinc claim 1 , copper claim 1 , nickel claim 1 , cobalt claim 1 , silver claim 1 , tungsten claim 1 , molybdenum claim 1 , zirconium claim 1 , vanadium claim 1 , chromium claim 1 , manganese claim 1 , iron claim 1 , cerium claim 1 , praseodymium claim 1 , samarium claim 1 , titanium and mixtures thereof.7. The process according to claim 1 , wherein the content of the promoter of the catalyst ranges from 0.005% to 500% claim 1 , by weight ...

Подробнее
07-11-2019 дата публикации

NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Номер: US20190337916A1
Принадлежит:

Compounds of formula (I) in the capacity of compounds with anti-tumor activity for the treatment of T-cell acute lymphoblastic leukemia (T-ALL). 2. The method according to claim 1 , wherein X and Y are carbon atoms bound by a double bond having claim 1 , independently claim 1 , an E or Z configuration.3. The method according to claim 1 , wherein{'sub': 1′', 'A', 'A', 'A', '2', 'A', '3', 'A', '2', 'A', '3', 'A', 'A', '3, 'R is hydrogen, halogen, OR, OC(═O)R, SR, SOR, SOR, OSOR, OSOR, C(R);'}{'sub': 2′', '3′', '1', '2', '3', 'B', 'B', 'B', 'B', 'B', '2', 'B', '3', 'B', '2', 'B', '3', 'B', 'B', '2', 'B', 'B', '2', 'B', '3, 'R, R, R, R, Rare the same or different and independently selected from: hydrogen; halogen; OR; C(═O)R; C(═O)OR; OC(═O)R; SR; SOR; SOR; OSOR; OSOR; N(R); NHC(═O)R; C(═O)N(R); C(R);'}{'sub': A', 'B', '1-7', '5-7', '5-7, 'at each occurrence, Rand Rare independently selected from: hydrogen; a linear or branched, saturated or unsaturated Caliphatic group optionally containing up to three heteroatoms independently selected from nitrogen, oxygen and sulfur; a Ccycloalkyl group; a phenyl group; a Cheterocyclic group;'}4. The method according to claim 1 , wherein{'sub': 1′', 'A', 'A', 'A', '2', 'A', '3', 'A', '2', 'A', '3', 'A', 'A', '3, 'R is hydrogen, halogen, OR, OC(═O)R, SR, SOR, SOR, OSOR, OSOR, C(R);'}{'sub': 2′', '3′', '1', '2', '3', '1-7', '5-7', '5-7, 'R, R, R, R, Rare the same or different and independently selected from: a linear or branched, saturated or unsaturated Cacyclic aliphatic group optionally containing up to three heteroatoms independently selected from nitrogen, oxygen or sulfur; a Ccycloalkyl group; a phenyl group; a Cheterocyclic group; and'}{'sub': 'A', 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'Rhas the meaning indicated in .'}5. The method according to claim 1 , whereinX and Y are carbon atoms bound by a double bond having, independently, an E or Z configuration;{'sub': 1′', 'A, 'R is OR;'}{'sub': '2′', 'R is hydrogen;'}{' ...

Подробнее
20-12-2018 дата публикации

Sacubitril intermediate and preparation method thereof

Номер: US20180362439A1
Принадлежит: Sunshine Lake Pharma Co Ltd

The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril. The method disclosed herein has advantages of easily obtained raw materials, simple preparation process, low cost, environment friendly, and etc., which is very suitable for industrial production.

Подробнее
19-12-2019 дата публикации

Inhibitors of the n-terminal domain of the androgen receptor

Номер: US20190382335A1

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

Подробнее
17-12-2020 дата публикации

PRODUCTION OF FRAMBINONE BY A RECOMBINANT FUNGAL MICROORGANISM

Номер: US20200392545A1
Принадлежит:

The invention relates to a genetically modified fungal microorganism for the production of frambinone, said microorganism having the following characteristics: —the capacity to produce frambinone from tyrosine; and —a limited capacity or no capacity to break tyrosine down into tyrosol, p-hydroxyphenylacetaldehyde and/or p-hydroxyphenylacetate; and to the use of same for producing frambinone. 110.-. (canceled)11. A process for the production of frambinone comprising culturing a fungal microorganism with a capacity to produce frambinone from tyrosine in a medium comprising tyrosine and a repressor of the path for breaking tyrosine down into tyrosol , p-hydroxyphenylacetaldehyde and/or p-hydroxyphenylacetate.12. The process for the production of frambinone according to characterized in that the repressor is glutamate.13. The process for the production of frambinone according to characterized in that the microorganism(a) belongs to the phyla chosen from among the ascomycetes or basidiomycetes,(b) includes at least one heterologous sequence encoding the enzyme 4-coumarate: CoA ligase (4CL) or benzalacetone synthase (BAS),(c) comprises at least one heterologous or supernumerary sequence encoding the enzyme tyrosine ammonia lyase (TAL) or benzalacetone reductase (BAR),(d) comprises at least one heterologous or supernumerary sequence encoding the enzyme phenylalanine ammonia lyase (PAL) or cinnamate 4 hydroxylase (C4H), or(e) comprises any combination of characteristics (a)-(d).14Saccharomyces cerevisiae. The process for the production of frambinone according to characterized in that the microorganism is the industrial strain RK4 registered with the CNCM on Jun. 1 claim 11 , 2016 under number I-5101.15Saccharomyces cerevisiae. The process for the production of frambinone according to characterized in that the microorganism is the industrial strain RK5 registered with the CNCM on Apr. 26 claim 11 , 2017 under number I-5199.16Yarrowia, Debaryomyces, Arxula, Scheffersomyces, ...

Подробнее
19-05-1994 дата публикации

Signal increase in immunoassays by inhibiting enzymatic catalysis.

Номер: DE3788048T2
Принадлежит: Becton Dickinson and Co

Подробнее
15-09-1988 дата публикации

Method of producing catechine derivatives

Номер: SU1424729A3

A catechol derivative represented by the formula wherein R' represents a hydrogen atom or a C, to C 5 alkyl group; R 2 represents a hydrogen atom or a halogen atom; X represents a straight chain or branched alkylene group having 1 to 15 carbon atoms or a vinylene group; Y represents a carbonyl group or a group represented by represents a hydrogen atom or a C, to C. alkyl group) and Z represents a hydrogen atom, a straight chain or branched alkyl group having 1 to 15 carbon atoms ora cycloalkyl group; the sum of the carbon atoms of said X and Z being at least 3. The compounds of this invention are useful for the prophylaxis and treatment for various allergic diseases, ischemic heart diseases an inflammations caused by slow reacting substance of anaphylaxis (SRS-A), since the compounds inhibit very potently the formation and release of SRS-A.

Подробнее
28-07-1988 дата публикации

α−ヒドロキシケトン類の製造法

Номер: JPS63183543A
Принадлежит: Daicel Chemical Industries Ltd

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Подробнее
01-12-1992 дата публикации

Gingerol og gingerdiolderivater som hypokolesterolemiske og antiatherosklerotiske midler

Номер: NO922151L
Принадлежит: Merrell Dow Pharma

Nye forbindelser av formelen. hvori er hydrogen eller C-C-alkyl, og Rer C-Calky1utviser tera-peutisk aktivitet.

Подробнее
12-06-2008 дата публикации

Novel curcumin and tetrahydrocurcumin derivatives

Номер: WO2008045534A3

The invention relates to novel curcumin and tetrahydrocurcumin derivatives, which have been modified at one phenolic group to incorporate more-reactive groups. The curcumin and tetrahydrocurcumin derivatives are in the form of monomers, dimmers, and polymers.

Подробнее
28-02-2012 дата публикации

Compositions and methods for modulating a kinase cascade

Номер: US8124605B2
Принадлежит: Kinex Pharmaceuticals LLC

The invention relates to compounds and methods for modulating one or more components of a kinase cascade.

Подробнее
09-12-2009 дата публикации

A new diaryl heptanoid and use of the same

Номер: KR100930480B1
Принадлежит: 주식회사 알앤엘바이오

PURPOSE: A diaryl heptanoid-based compound is provided to be used for the treatment and prevention of disease by virus activity, especially to be useful for activity inhibition of avian influenza virus. CONSTITUTION: A diaryl heptanoid-based compound, its isomer or its pharmaceutically acceptable salts has a structure represented by chemical formula 1. In the chemical formula 1, Z is hydrogen or hydroxy and a dotted line is an arbitrary double bond. The virus is influenza virus or avian influenza virus. A pharmaceutical composition for the treatment of diseases according to infection and/or prevention of virus comprises the diaryl heptanoid-based compound and pharmaceutically acceptable carrier.

Подробнее
12-08-2020 дата публикации

Antimicrobial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and chlorphenezin, and a cosmetic composition containing it

Номер: RU2729821C1
Принадлежит: Л'Ореаль

FIELD: chemistry.SUBSTANCE: present invention relates to an antimicrobial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and chlorphenezin, as well as to a cosmetic composition containing such a mixture.EFFECT: is used for care of keratin-containing materials, application of make-up on them and their cleaning.6 cl, 2 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 729 821 C1 (51) МПК A01N 31/14 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A01N 31/14 (2020.02) (21)(22) Заявка: 2020103425, 27.06.2018 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Л'ОРЕАЛЬ (FR) Дата регистрации: 12.08.2020 30.06.2017 FR 1756153 (45) Опубликовано: 12.08.2020 Бюл. № 23 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 30.01.2020 (86) Заявка PCT: WO 2019/002396 (03.01.2019) Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" (54) ПРОТИВОМИКРОБНАЯ СМЕСЬ, СОДЕРЖАЩАЯ 4-(3-ЭТОКСИ-4-ГИДРОКСИФЕНИЛ)БУТАН2-ОН И ХЛОРФЕНЕЗИН, И КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ (57) Реферат: Настоящее изобретение относится к композиции, содержащей такую смесь. противомикробной смеси, содержащей 4-(3Применяется для ухода за кератиносодержащими этокси-4-гидроксифенил)бутан-2-он и материалами, нанесения на них макияжа и их хлорфенезин, а также к косметической очистки. 2 н. и 4 з.п. ф-лы. 2 пр. R U 2 7 2 9 8 2 1 (87) Публикация заявки PCT: Стр.: 1 C 1 C 1 EP 2018/067304 (27.06.2018) 2 7 2 9 8 2 1 (56) Список документов, цитированных в отчете о поиске: RU 2535010 C2, 10.12.2014. RU 2623241 C2, 23.06.2017. US 2012251460, 04.10.2012. US 2011152383, 23.06.2011. Приоритет(ы): (30) Конвенционный приоритет: R U 27.06.2018 (72) Автор(ы): МАЛЕ, Гаэль (FR), КЮПФЕРМАН, Сильви (FR) RUSSIAN FEDERATION (19) RU (11) (13) 2 729 821 C1 (51) Int. Cl. A01N 31/14 (2006.01) FEDERAL SERVICE FOR INTELLECTUAL PROPERTY (12) ABSTRACT OF INVENTION (52) CPC A01N 31/14 ( ...

Подробнее
13-11-2013 дата публикации

Novel diaryl hepatonoid-based compound and use thereof

Номер: CN102112427B
Принадлежит: RNL Bio Co Ltd

本发明涉及具有病毒抑制活性的化学式(1)的新型二芳基庚酮类化合物;其药物学上可接受的盐;或水合物,前述任何物质的溶剂化物或前药,和包含其的药物组合物,和其治疗剂的用途。二芳基庚酮类化合物具有抑制病毒活性的卓越功效,这样作为对抗病毒相关的疾病的治疗剂是有用的。

Подробнее
15-02-1983 дата публикации

Process for preparing derivatives of imidazole or their hydrochlorides

Номер: SU997607A3

The invention provides compounds of the formula: wherein R 1 , R 2 and R 3 , which can be the same or different, are each selected from hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxy, amino, hydroxy and nitro; R 4 is hydrogen or alkyl of 1 to 7 carbon atoms; -X- is wherein R 5 is hydrogen, hydroxy or-OR 6 , and R 6 is alkyl of 1 to 7 carbon atoms or aryl of 6 to 10 carbon atoms; and their non-toxic pharmaceutically acceptable acid addition salts and mixtures thereof. Processes for the preparation and use of the subject compounds are described, as are novel pharmaceutical compositions comprising at least one of the subject compounds or their salts. The compounds and their non-toxic salts exhibit valuable pharmacological activity and are useful in the treatment of mammals, particularly as anti-hypertensive or anti-ulcer agents. Furthermore, they are useful as diuretic, sedative, analgesic, anti-inflammatory and tranquilizing agents.

Подробнее
18-02-2013 дата публикации

A preparation method of all-carbon quaternary stereocenter compound using 2,2-disubstituted 1,3-propanediol

Номер: KR101233809B1
Автор: 강성호, 유영석, 이지영
Принадлежит: 한국과학기술원

본 발명은 2,2 위치에 2 개의 치환기를 갖는 1,3-프로판디올을 이용한 탄소만을 가지는 4급 탄소 입체중심 화합물의 제조방법에 관한 것으로서, 보다 상세하게는 키랄 리간드로서 부틸기로 치환된 피리딘비스옥사졸린과 2가 구리 화합물의 복합체를 사용하여 2,2 위치에 2 개의 치환기를 갖는 1,3-프로판디올의 촉매적 비대칭화를 통해 탄소만을 가지는 4급 입체중심 탄소 화합물을 제조하는 방법에 관한 것이다. The present invention relates to a method for preparing a quaternary carbon stereocenter compound having only carbon using 1,3-propanediol having two substituents at the 2,2 position, and more particularly, pyridine bis substituted with a butyl group as a chiral ligand. A method for preparing a quaternary stereocentered carbon compound having only carbon by catalytic asymmetry of 1,3-propanediol having two substituents at the 2,2 position using a complex of oxazoline and a divalent copper compound will be.

Подробнее
10-09-2021 дата публикации

Moisture curable polyolefin formulations

Номер: CN113383039A
Принадлежит: Dow Global Technologies LLC

一种可湿固化聚烯烃调配物,其包含(可水解甲硅烷基)官能的聚烯烃预聚物和缩合‑固化催化剂系统,所述催化剂系统包含为甲脒或胍的化合物和为乙酰丙酮钴或乙酰丙酮锌的化合物的混合物和/或由其制备,其中各化合物独立地为未取代或取代的。此外,其制备和使用方法、一种由其制备的固化聚烯烃,以及包含或由其制成的制品。此外,缩合‑固化催化剂系统可用于其中。

Подробнее
04-05-2018 дата публикации

Chalcone derivatives, optical isomer thereof, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition for preventing or treating mitochondrial disease induced by decrease of oxygen consumption rate comprising the same as an active ingredient

Номер: KR101855087B1

The present invention relates to a chalcone derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the chalcone derivative compound as an active ingredient, a neurodegenerative disease, attention deficit hyperactivity disorder, asthma, drug poisoning, chronic renal failure, The present invention relates to a pharmaceutical composition for preventing or treating a disease caused by a decrease in oxygen consumption rate of mitochondria selected from liver diseases, wherein the chalcone derivative compound has excellent activity of increasing the oxygen consumption rate in mitochondria, Or a pharmaceutically acceptable salt thereof.

Подробнее
12-10-2018 дата публикации

1,5-diphenyl-penta-1,4-dien-3-one compounds

Номер: KR101907631B1

본 발명은 1,5-디페닐펜타-1,4-디엔-3-온 화합물 골격을 함유하는 명세서 내에 나타낸 바와 같은 화학식 (I), (II), 또는 (III)의 화합물에 관한 것이다. 이들 화합물은 암, 염증성 질환, 또는 자가면역 질환의 치료에 사용될 수 있다. The present invention relates to compounds of formula (I), (II), or (III) as shown in the specification containing a 1,5-diphenylpentane-1,4-dien-3-one compound backbone. These compounds can be used for the treatment of cancer, inflammatory diseases, or autoimmune diseases.

Подробнее
23-04-1983 дата публикации

Process for preparing derivatives of imidazole

Номер: SU1014472A3

The invention provides compounds of the formula: wherein R 1 , R 2 and R 3 , which can be the same or different, are each selected from hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxy, amino, hydroxy and nitro; R 4 is hydrogen or alkyl of 1 to 7 carbon atoms; -X- is wherein R 5 is hydrogen, hydroxy or-OR 6 , and R 6 is alkyl of 1 to 7 carbon atoms or aryl of 6 to 10 carbon atoms; and their non-toxic pharmaceutically acceptable acid addition salts and mixtures thereof. Processes for the preparation and use of the subject compounds are described, as are novel pharmaceutical compositions comprising at least one of the subject compounds or their salts. The compounds and their non-toxic salts exhibit valuable pharmacological activity and are useful in the treatment of mammals, particularly as anti-hypertensive or anti-ulcer agents. Furthermore, they are useful as diuretic, sedative, analgesic, anti-inflammatory and tranquilizing agents.

Подробнее
12-03-1974 дата публикации

Patent JPS4910664B1

Номер: JPS4910664B1
Автор: [UNK]
Принадлежит: [UNK]

Подробнее
09-09-2004 дата публикации

Curcumin analogs with anti-tumor and anti-angiogenic properties

Номер: US20040176384A1
Принадлежит: EMORY UNIVERSITY

The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.

Подробнее
07-09-2021 дата публикации

Catalytic oxidation of 3-butene-1, 2-diol (BDO)

Номер: CN107001215B
Принадлежит: Adisseo Ireland Ltd

本发明涉及下式(I)化合物或其盐之一的合成方法, 其中式(I)的R表示COOH,CH 2 OH或CHO基团,所述方法包括在催化剂存在下使3‑丁烯‑1,2‑二醇(BDO)进行氧化的步骤,所述催化剂包含基于至少一种贵金属的活性相,所述贵金属选自钯,金,银,铂,铑,锇,钌和铱以及含碱性载体的载体。本发明还涉及该反应在制备生物可利用的甲硫氨酸化合物的应用,特别是用于动物营养。

Подробнее
08-04-2011 дата публикации

Use of at least one substituted 2-propyl-phenol compound as a preservative in a cosmetic, dermatological, pharmaceutical, nutraceutical or oral cosmetic composition, which is useful as e.g. a makeup product for facial skin, body or lips

Номер: FR2950885A1
Принадлежит: LOreal SA

La présente invention concerne l'utilisation, dans une composition cosmétique, dermatologique ou pharmaceutique, d'au moins un composé de formule (1) : dans laquelle : - n représente un entier compris entre 0 et 3 (inclus); - R représente un radical méthyle ou éthyle; - R2 représente un atome d'hydrogène, un radical méthyle ou un radical éthyle; - R3 représente un radical alkyle linéaire ou ramifié, saturé en C1-C12 ou insaturé en C2-C12; - X est =O ou OH; en tant qu'agent conservateur. L'invention concerne également certains composés de formule (I) ainsi que les compositions cosmétiques, dermatologiques ou pharmaceutiques les comprenant.

Подробнее
14-08-1980 дата публикации

6-ALKYL DERIVATIVES OF 1,2-DIHYDRO-2-OXONICOTINIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING THEM

Номер: FR2446819A1
Автор: [UNK]
Принадлежит: Upjohn Co

L'invention a trait au domaine de la chimie pharmaceutique. Elle concerne certains nouveaux dérivés 6-alkyliques d'acide 1,2-dihydro-2-oxonicotinique de formule : The invention relates to the field of pharmaceutical chemistry. It relates to certain new 6-alkyl derivatives of 1,2-dihydro-2-oxonicotinic acid of formula:

Подробнее
04-06-1971 дата публикации

Patent FR2059538A1

Номер: FR2059538A1
Автор: [UNK]
Принадлежит: Takeda Chemical Industries Ltd

Подробнее
29-04-1999 дата публикации

Medicinal uses of phenylalkanols and derivatives

Номер: CA2307028A1

A compound of formula (I), a pharmaceutically acceptable derivative thereof, wherein Ph is a phenyl radical R1 is H, OH, OC1-4alkyl, NO2; R2 is OH, OC1-4alkyl, OC=OC1-4alkyl or OC=OPh where the Ph can be optionally substituted by halogen, C1-3 alkyl or NO2; R1 and R2 along with the two carbon atoms of the phenyl ring to which they are attached can combine to form a 5 or 6 membered heterocyclic ring comprising 1 or 2 heteroatoms selected from O, S or N; R3 is an optionally substituted hydrocarbyl radical; R4 is H, CH3, OH or =O; when R4 is =O, then the carbon to which R4 is attached is not bonded to H; W is C(=O)-CH2, CH=CH-, CH2CO, CH(OH)-CH2, C(CH3)(OH)CH2, CH2CH(OH), CH2C(CH3)OH, CO, CHOH, C(CH3)(OH), CH2, CH2CH2; X is -CH-OH, C(CH3)OH, CH2, CH(CH3) or -C=O; Y is -CH-OH, C(CH3)OH, CH2, CH(CH3) or -C=O; provided that one of W, X or Y has an OH group.

Подробнее
18-11-1980 дата публикации

Beta-substituted-diketones and preparation thereof

Номер: CA1089864A
Автор: Guy D. Diana
Принадлежит: Sterling Drug Inc

ABSTRACT OF THE DISCLOSURE Beta-diketones substituted by an aryl-aliphatic group in which the aliphatic chain is interrupted by a cyclic group, and useful as anti-viral agents, are prepared by interacting the appropriate aryl-aliphatic halide with an alkali metal salt or a beta-diketone.

Подробнее
19-10-1984 дата публикации

Patent FR2496638B1

Номер: FR2496638B1
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
08-04-2011 дата публикации

USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, METHOD OF PRESERVATION, COMPOUNDS AND COMPOSITION

Номер: FR2950805A1
Автор: Maria Dalko
Принадлежит: LOreal SA

La présente invention concerne l'utilisation, dans une composition cosmétique, dermatologique ou pharmaceutique, d'au moins un composé de formule (I) : dans laquelle - R2 représente un atome d'hydrogène ou un radical méthyle ou éthyle; - R3 représente un radical alkyle linéaire en C1-C12, éventuellement substitué par un groupe hydroxyle; ou bien un radical alcényle linéaire en C2-C12, éventuellement substitué par un groupe hydroxyle. en tant qu'agent conservateur. L'invention concerne également certains composés nouveaux et les compositions cosmétiques, dermatologiques ou pharmaceutiques les comprenant. The present invention relates to the use, in a cosmetic, dermatological or pharmaceutical composition, of at least one compound of formula (I): in which - R2 represents a hydrogen atom or a methyl or ethyl radical; - R3 represents a linear C1-C12 alkyl radical, optionally substituted with a hydroxyl group; or a C2-C12 linear alkenyl radical, optionally substituted with a hydroxyl group. as a conservative agent. The invention also relates to certain novel compounds and cosmetic, dermatological or pharmaceutical compositions comprising them.

Подробнее
27-11-1981 дата публикации

Patent FR2401897B1

Номер: FR2401897B1
Автор: [UNK]
Принадлежит: Sterling Drug Inc

Подробнее
11-10-1974 дата публикации

Hydroxy phenyl substd ketones - useful as flavourings and aromatising agents

Номер: FR2221433A1
Автор: [UNK]

Hydroxyphenyl-substd. ketones (I) where R = alkyl, are made by hydrolysing cpds (II): where R" = alkyl. The cpds (II) are made by (a) reacting 4-hydroxybenzylalcohol in the presence of a base with a cpd RCOCH2COOR" (III) or (b) reacting phenol in the presence of an acid with a cpd.

Подробнее
11-10-1974 дата публикации

Patent FR2059538B1

Номер: FR2059538B1
Автор: [UNK]
Принадлежит: Takeda Chemical Industries Ltd

Подробнее
02-12-2016 дата публикации

CATALYTIC OXIDATION OF BUT-3-ENE-1,2-DIOL

Номер: FR3029518B1
Принадлежит: Adisseo France SAS

Подробнее
17-04-2008 дата публикации

Novel curcumin and tetrahydrocurcumin derivatives

Номер: CA2665916A1

The invention relates to novel curcumin and tetrahydrocurcumin derivatives, which have been modified at one phenolic group to incorporate more-reactive groups. The curcumin and tetrahydrocurcumin derivatives are in the form of monomers, dimmers, and polymers.

Подробнее
08-09-1941 дата публикации

Process for the manufacture of ketoalcohols

Номер: FR866827A
Автор:
Принадлежит: ISTITUTO PER LO STUDIO DELLA G

Подробнее
08-04-2011 дата публикации

USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, METHOD OF PRESERVATION, COMPOUNDS AND COMPOSITION

Номер: FR2950884A1
Автор: Maria Dalko
Принадлежит: LOreal SA

La présente invention concerne l'utilisation, dans une composition cosmétique, dermatologique ou pharmaceutique, d'au moins un composé de formule (1) : dans laquelle - R2 représente un atome d'hydrogène ou un radical méthyle ou éthyle; - R3 représente un radical alkyle linéaire en C1-C12, éventuellement substitué par un groupe hydroxyle; ou bien un radical alcényle linéaire en C2-C12, éventuellement substitué par un groupe hydroxyle. en tant qu'agent conservateur. L'invention concerne également certains composés nouveaux et les compositions cosmétiques, dermatologiques ou pharmaceutiques les comprenant. The present invention relates to the use, in a cosmetic, dermatological or pharmaceutical composition, of at least one compound of formula (1): in which - R2 represents a hydrogen atom or a methyl or ethyl radical; - R3 represents a linear C1-C12 alkyl radical, optionally substituted with a hydroxyl group; or a C2-C12 linear alkenyl radical, optionally substituted with a hydroxyl group. as a conservative agent. The invention also relates to certain novel compounds and cosmetic, dermatological or pharmaceutical compositions comprising them.

Подробнее
01-10-2009 дата публикации

Process for the preparation of 4-(4-hydroxyphenyl)butan-2-one using solid acid clay catalyst

Номер: CA2719274A1

Solid acid catalyst such as acid activated-Montmorillonite clay composite has been developed by modifying the Na-Montmorillonite clay with acid (HC1) treatment for different periods such as 5 minutes to about 4 hours and activating at about 120°C for about 2 hours. Friedel Crafts alkylation reaction between phenol and 4-hydroxybutan-2-one in presence of the acid activated Montmorillonite clay catalysts exhibiting layered clay structures (basal spacing d001 ranging from about 10 to 13.5 .ANG.), high surface area (250 - 400 m2/g), highly porous {micropores in the range 5 to 15 .ANG. and mesopores in the range 30 to 80 .ANG.}, average pore volume 0.2 to 0.65 cc/g, and surface acidity in the range 0.4 - 0.6 mmol/g; under constant stirring and at pressure of 1-15 bar, temperature 100 - 150°C for a period of about 12 - 24 hours produces 4-(4-hydroxyphenyl)butan-2-one (Raspberry ketone) exhibiting conversion about 35 - 55 % and high selectivity in the range 75 -81 %.

Подробнее
17-05-2013 дата публикации

USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, METHOD OF PRESERVATION, COMPOUNDS AND COMPOSITION

Номер: FR2950805B1
Автор: Maria Dalko
Принадлежит: LOreal SA

Подробнее
31-07-1980 дата публикации

Organic compound and pharmaceutic composition

Номер: JPS55100363A
Принадлежит: Upjohn Co

Подробнее
14-02-1984 дата публикации

3,5-di-Tert-butylstyrene derivatives, salts thereof, and pharmaceutical compositions containing the same as an active ingredient

Номер: US4431656A
Принадлежит: Kanegafuchi Chemical Industry Co Ltd

Novel compounds, 3,5-di-tert-butylstyrene derivatives and their salts, are disclosed, which derivatives are represented by the general formula: ##STR1## wherein R 1 stands for an acyloxy group represented by R 3 COO (R 3 is a hydrogen atom or an alkyl group with C 1 -C 6 ), an alkoxyl group of R 4 O (R 4 is an alkyl group with C 1 -C 4 ), a hydroxyl group, or a hydrogen atom; R 2 stands for ##STR2## (R 5 is a hydrogen atom or an alkyl group with C 1 -C 3 and X 1 is CH 2 or an oxygen atom), ##STR3## (R 5 and X 1 are each the same as defined above), or ##STR4## (X 2 is an oxygen or sulfur atom). There are also disclosed an anti-inflammatory, analgesic, and antipyretic pharmaceutical composition and an anti-platelet aggregation pharmaceutical composition, both pharmaceutical compositions comprising the foregoing 3,5-di-tert-butylstyrene derivative or its pharmaceutically acceptable salt as an active ingredient in association with pharmaceutical excipients.

Подробнее
11-03-2014 дата публикации

Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof

Номер: CA2674780C
Принадлежит: AndroScience Corp

The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of many medical conditions such as androgen associated conditions. The present invention also includes methods of treating a medical condition including an androgen associated condition, using at least one of the disclosed compounds.

Подробнее